

INVITED LECTURES

Prof. Dr. med. Dr. h.c. M. Oellerich
FADLM, FAMM, FFPATH (RCPI), FRCPath

Distinguished Research Professor
of Clinical Chemistry

1. Erfahrungsbericht über ein dünnschichtchromatographisches Screening-Verfahren zum Nachweis von Drogen im menschlichen Urin (Drug Screen). Jahrestagung der Deutschen Gesellschaft für Klinische Chemie, Hannover, 13.-14.09.1973.
Abstract: Z. Klin. Chem. Klin. Biochem. 12, 44 (1974).
2. Vergleichende Untersuchungen zum Drogennachweis im Urin mit Enzymimmunoassay (EMIT) und Dünnschicht-Chromatographie. (Drug Screen). Analytica 76, München, 10.04.1976.
Abstract: Z. Anal. Chem. 279, 132 (1976).
3. Quantitative determination of phenobarbital and diphenylhydantoin in serum by enzyme immunoassay.
2nd European Congress on Clinical Chemistry, Prag, 5.10.1976.
4. Phenyläthylhydrazonopyruvat, eine neue hypoglykämisch wirksame Substanz. Klinisch-chemisches Kolloquium, Hannover, 30.11.1976.
5. Vergleichbarkeit der Digoxin-Bestimmung mit verschiedenen Immunotests. Medica, 77. Seminar: "Vergleichbarkeit von Laboratoriumswerten", Düsseldorf, 18.11.1977.
6. Comparison of enzyme immunoassay (EMIT) with four radioimmunoassays for determination of digoxin.
X. International Congress of Clinical Chemistry, Mexico, 27.02.1978.
7. Einsatz von Enzymimmunotests beim Drogenscreening.
Wissenschaftliche Fortbildungstagung für Laboratoriumsmedizin, Obergurgl, 12.04.1978.
8. Enzymimmunoassay. Anwendung in der Routinediagnostik.
Leitung eines wissenschaftlichen Praktikums mit mehreren Vorträgen, Analytica 78, München, 18.-19.04.1978.
9. Die hypoglykämische Wirkung der Phenyläthylhydrazono- und Cyclohexyl-äthylhydrazonopropionsäure.
Sektionssitzung, Medizinische Hochschule Hannover, Hannover, 11.05.1978.
10. Anwendung von Enzymimmunotests in der Routinediagnostik.
Klinisch-chemisches Kolloquium, Hannover, 28.06.1978.
11. Handhabung und Applikation von ELISA Tests.
Workshop der Firma Boehringer Mannheim, Tutzing, 05.07.1978.
12. Untersuchungsmaterial für klinisch-chemische Bestimmungen - Proben, Einflußgrößen und Störfaktoren.
Fortbildungskurs der Gesellschaft Deutscher Chemiker, Hannover, 17.10.1978.
13. Spezielle immunologische Untersuchungsverfahren.
Fortbildungskurs der Gesellschaft Deutscher Chemiker, Hannover, 20.10.1978.
14. Überwachung der Serumspiegel des Theophyllins und einiger Antiepileptika.
Seminar, Kinderklinik, Medizinische Hochschule Hannover, Hannover, 15.11.1978.

15. Die vollmechanisierte Bestimmung von Theophyllin mit dem homogenen Enzymimmunotest.
Seminar "Enzymimmunoassay", Medica 78, Düsseldorf, 22.11.1978.
16. Anwendung der EMIT-Technik beim Drogenscreening.,
Seminar "Enzymimmunoassay", Medica 78, Düsseldorf, 22.11.1978.
17. Anwendung von Enzymimmunotests in der Routinediagnostik.
Fortbildungsvortrag für Laborärzte, Berlin, 14.12.1978.
18. Hydrazonopropionsäuren - eine neue Gruppe oral wirksamer, blutglucosesenkender Substanzen.
Antrittsvorlesung, Medizinische Hochschule Hannover, Hannover, 03.02.1979.
19. Enzymimmunotests für die Diagnostik - gegenwärtiger Stand und Entwicklungstendenzen.
Plenarvortrag, Gemeinsame Jahrestagung der Österreichischen Gesellschaft und Deutschen Gesellschaft für Klinische Chemie, Salzburg, 31.03.1979.
20. Einsatz der Dünnschichtchromatographie und EMIT-Technik beim Drogen-Screening.
Kongreß der Deutschen Gesellschaft für Laboratoriumsmedizin, Berlin, 02.05.1979.
21. Die Bestimmung von Methotrexat mit einem vollmechanisierten Enzymimmunotest.
Kongreß der Deutschen Gesellschaft für Laboratoriumsmedizin, Berlin, 03.05.1979.
22. Einsatz von Enzymimmunotests in der Schilddrüsendiagnostik und bei der Überwachung des Digoxinspiegels im Serum.
Fortbildungsveranstaltung der Firma Boehringer Mannheim, Bernried, 31.05.1979.
23. Die Bestimmung von Methotrexat mit einem vollmechanisierten homogenen Enzymimmunotest.
Seminar, Hämatologie, Medizinische Hochschule Hannover, Hannover, 12.06.1979.
24. Erfahrungsbericht über einen Enzymimmunotest (ENZYMUN) zur Bestimmung von TSH im Serum.
Workshop der Firma Boehringer Mannheim, Frankfurt, 03.08.1979.
25. Einsatz von Enzymimmunotests in der Klinischen Toxikologie.
Senatskommission für klinisch-toxikologische Analytik, Bonn-Bad Godesberg, 17.09.1979.
26. Gegenwärtiger Stand und Trends bei Enzymimmunotests für die Diagnostik. Analytik in der klinischen Chemie.
Symposium der Österreichischen Gesellschaft für Klinische Chemie, Graz, 16.10.1979.
27. Methodik der Theophyllin-Bestimmung.
Arbeitsgespräch über die Optimierung der Asthma-Therapie mit Theophyllin-Präparaten durch Bestimmung der Blutspiegel, Bad Lippspringe, 02.11.1979.
28. Blutglucosesenkung durch eine neue Gruppe von Hydrazonverbindungen.
Vortragsveranstaltung am Institut für Klinische Chemie und Pathiobiochemie, Gießen, 08.12.1979.

29. Homogeneous vs. heterogeneous enzyme immunoassay; instrumentation; data processing; fields of application; drugs.
Workshop Enzyme-Immunoassay, Analytica 80, München, 29.04.1980.
30. Enzymimmuntests - praktische Anwendung in der Routinediagnostik.
Leitung eines wissenschaftlichen Praktikums mit mehreren Vorträgen. Analytica 80, München 30.04. und 01.05.1980.
31. Drug-Monitoring.
Klinisch-chemisches Kolloquium, Hannover, 29.05.1980.
32. Bioavailability of various sustained-release theophylline formulations.
Symposium on therapeutic drug monitoring, Guildford, England, 01.08.1980.
33. Indikation und Methodik der Bestimmung des Serum-Theophyllin-Spiegels.
2. Internationales Symposium über orale Theophylline zur Behandlung obstruktiver Atemwegserkrankungen, Zürich, 27.09.1980.
34. Evaluation of a heterogeneous enzyme immunoassay for determination of triiodothyronine.
Joint Congress of the Scandinavian and German Societies of Clinical Chemistry, Hamburg, 10.10.1980.
Abstract: J. Clin. Chem. Clin. Biochem. 18, 718 (1980).
35. Enzymimmuntests - Prinzip und Anwendung in der klinisch-chemischen Routinediagnostik.
Fortbildungsveranstaltung für medizinisch-technische Assistentinnen, Garbsen, 17.10.1980.
36. Enzymimmunoassays für Thyroxin, Trijodthyronin und Thyroxin-Bindungs-Kapazität.
Seminar: "Strahlungslose Schilddrüsendiagnostik", Medica 80, Düsseldorf, 21.11.1980.
37. Drug Monitoring mit Enzymimmuntests.
Seminar: Neue praktische Anwendungsgebiete des Enzymimmunoassays in der klinischen Chemie und Serologie. Medica 80, Düsseldorf, 22.11.1980.
38. Einfluß von Arzneimitteln auf die Bestimmung von Pharmaka mit Enzymimmuntests.
Kleinkonferenz der Deutschen Gesellschaft für Klinische Chemie: "Beeinflussung klinisch-chemischer Kenngrößen durch Arzneimittel". Schloß Auel, Lohmar, 09.01.1981.
39. Neuere Entwicklungen der Mechanisierung von Enzymimmuntests.
Deutscher MTA-Kongreß, Mannheim, 20.03.1981.
40. Klinische Erfahrungen mit der Bestimmung des Theophyllin-Spiegels im Serum bei Patienten mit obstruktiven Ventilationsstörungen.
4. Internationales Symposium "Methoden der Klinischen Pharmakologie - Theophyllin und andere Methylxanthine", Frankfurt, 30.05.1981.

41. Drug Monitoring - Methodik und klinische Bedeutung.
Instituts-Kolloquium des Instituts für Klinische Chemie der Ludwig-Maximilians-Universität München, Klinikum Großhadern, München, 14.07.1981.
42. Monitoring therapeutic drugs in clinical chemical laboratories.
XI International Congress of Clinical Chemistry, Vienna, 03.09.1981.
Abstract: J. Clin. Chem. Clin. Biochem. 19, 575 (1981).
43. Indikation und Methodik der Theophyllin-Bestimmung im Serum.
Fortbildungsvortrag. Zentrum für Innere Medizin und Dermatologie, Medizinische Hochschule Hannover, Hannover, 21.10.1981.
44. Erfahrungsbericht über die Bestimmung der Ó-Amylase mit einem neu entwickelten Testverfahren (RapignostR-Amylase).
Amylase-Symposium, Marburg/Lahn, 06.11.1981.
45. Drug Monitoring.
Fortbildungsvortrag. Zentrum für Innere Medizin und Dermatologie, Medizinische Hochschule Hannover, Hannover, 11.11.1981.
46. Drug Monitoring - Aufgaben des klinisch-chemischen Labors.
Medica 81, Seminar: "Therapeutic Drug Monitoring - ein neuer Weg zum effektiven Einsatz hochwirksamer Arzneimittel", Düsseldorf, 18.11.1981.
Abstract: Medica 2, 71 (1981).
47. Drug Monitoring - analytische und klinische Aspekte.
Lesser-Loewe-Kolloquium. Klinikum der Stadt Mannheim, Mannheim, 13.01.1982.
48. Therapie mit Theophyllin: Indikation und Nutzen der Konzentrationsbestimmung von Theophyllin im Serum.
Fortbildungsveranstaltung für Ärzte, Bürgerhospital, Stuttgart, 14.10.1982.
49. Einsatz des RapignostR-Amylase-Teststreifens in der Diagnostik der akuten Pankraetitis.
Fortbildungsveranstaltung der Firma Behring, Hannover, 19.03.1982.
50. TBG-Bestimmung bei eu- und hypothyreoten Patienten.
Workshop der Firma Boehringer Mannheim, Murnau, 02.04.1982.
51. Determination of theophylline in serum by non-isotopic immunoassays (EMIT, SLFIA, NIIA) and HPLC - a comparative study.
Analytica 82, München, 28.04.1982.
52. Drug Monitoring - methodische und klinische Erfahrungen.
Seminar der Firma Boehringer Mannheim, Tutzing, 29.04.1982.
53. Bestimmung der Theophyllin-Konzentration im Serum mit Immunotests und Hochdruckflüssigkeitschromatographie.
Sitzung der Arbeitsgruppe "Drug Monitoring" der Senatskommission für klinisch-toxikologische Analytik, Hannover, 26.05.1982.
54. Advances in drug assay methodology. 14th Epilepsy International Symposium 1982, London, 15.08.1982.

55. Optimierte Dosierung von Theophyllin durch Abschätzung der Clearance mit einer einfachen pharmakokinetischen Methode.
3. Internationales Symposium über orale Theophylline zur Behandlung obstruktiver Atemwegserkrankungen. Montreux, 18.09.1982.
56. Drug Monitoring - Methodik und Qualitätskontrolle.
Jahrestagung der Deutschen Gesellschaft für Klinische Chemie. Stuttgart, 24.09.1982.
Abstract: J. Clin. Chem. Clin. Biochem. 20, 659 (1982).
57. Future of drug monitoring: new developments for drug measurement.
Biologie prospective. 5e colloque international de pont-à-mousson, Pont-à-Mousson, 07.10.1982.
Abstract: Ann. Biol. Clin. 40, 395 (1982).
58. Probleme des Drug Monitoring im klinisch-chemischen Laboratorium.
Vortragsveranstaltung der Universität Marburg, Marburg, Lahn, 01.11.1982.
59. Drug-Monitoring und Dosisvorhersage.
Theophyllin Workshop, St. Paul, 20.11.1982.
60. Diagnostik des Drogenabusus mit klinisch-chemischen Methoden.
Internationales Symposium: Drogen- im Kindes- und Jugendalter. 34. Jahrestagung der Deutschen Gesellschaft für Sozialpädiatrie. München, 26.11.1982.
61. Drug Monitoring bei der Therapie mit Theophyllin-Methodik und Dosisvorhersage.
Vortragsveranstaltung der Ruhr-Universität Bochum, Bochum, 02.12.1982.
62. Analytische und klinische Aspekte des Therapeutischen Drug Monitoring.
Kolloquium des Zentrallabors der Universität Göttingen. Arbeitstagung: Therapeutisches Drug Monitoring, Göttingen, 19.01.1983.
63. Evaluation of non-isotopic immunoassays for therapeutic drug monitoring.
Royal Infirmary Hospital, Department of Biochemistry, Glasgow, 01.02.1983.
64. Dosisvorhersage mit einem einfachen pharmakokinetischen Verfahren.
Fortbildungsvortrag für Ärzte, Zentrum für Innere Medizin und Dermatologie, Medizinische Hochschule Hannover, Hannover, 23.02.1983.
65. Drug monitoring by non-isotopic immunoassays (EMIT, FPIA, SLFIA, NIIA).
Fortbildungsveranstaltung, Lund, 02.03.1983.
66. Therapieüberwachung durch Bestimmung von Pharmakakonzentrationen im Serum.
Fortbildungsveranstaltung für Ärzte, Kreiskrankenhaus Sande, 09.03.1983.
67. Das Konsilium im Rahmen der klinischen Toxikologie und des Drug Monitoring.
Kleinkonferenz der Deutschen Gesellschaft für Klinische Chemie: "Das Konsilium in der Klinischen Chemie". Frankfurt, 12.03.1983.
68. Vorhersage der Erhaltungsdosis von Theophyllin mit einer einfachen pharmakokinetischen Methode.
Kolloquium des Instituts für Klinische Chemie, Medizinische Hochschule Hannover, Hannover, 13.04.1983.

69. Therapieüberwachung durch Bestimmung von Pharmakakonzentrationen im Serum. Fortbildungsveranstaltung für Ärzte. Städt. Krankenhaus, Frankfurt-Höchst, 20.04.1983.
70. Evaluation von radioaktivitätsfreien Immunotests (EMIT, FPIA, SLFIA, NIIA) zur Bestimmung von Pharmakakonzentrationen im Serum. Kongreß für Laboratoriumsmedizin. Abstract: Lab. med. 7, 133 (1983).
71. Bestimmung von Phenytoin im Serum und Ultrafiltrat mit radioaktivitätsfreien Immunotests. Sitzung der Arbeitsgruppe "Drug Monitoring" der Senatskommission für klinisch-toxikologische Analytik der Deutschen Forschungsgemeinschaft, Hannover 26.05.1983.
72. Analytical aspects of drug monitoring. Symposium: Intéret clinique du dosage des médicaments, Paris, 30.05.1983.
73. Concepts of drug monitoring. Symposium: Intéret clinique du dosage des médicaments, Paris 30.05.1983.
74. Konzepte des Drug Monitoring. Symposium: Optimierung der Pharmakotherapie mittels Drug Monitoring, Essen 31.05.1983.
75. Analytische Aspekte des Drug Monitoring. Symposium: Optimierung der Pharmakotherapie mittels Drug Monitoring, Essen, 31.05.1983.
76. Therapiekontrolle durch Bestimmung der Serumkonzentrationen von Pharmaka. Medizinische Gesellschaft, Düsseldorf, 08.06.1983.
77. Enzymimmunologische Methoden. Kleinkonferenz der Deutschen Gesellschaft für Klinische Chemie: Immunologische Diagnostik, Hamburg 10.06.1983.
78. Drug monitoring-evaluation of non-isotopic immunoassays and methods for dosage prediction. Seminar, North Chicago, 01.08.1983.
79. Drug monitoring with non-isotopic immunoassays and methods for dasage prediction. Seminar, Dallas, 02.08.1983.
80. Use of non-protein bound drug concentrations as a guide to individualization of drug therapy: current status and new developments. Special seminar, University of Tennessee, Center for the Health Sciences Memphis, 03.08.1983.
81. Ultrafiltration vs. ultracentrifugation: comparison of methods. Satellite Symposium of II World Conference on Clinical Pharmacology and Therapeutics: clinical implications of drug-protein-binding. Washington, 06.08.1983.

82. Methodische und klinische Aspekte der Bestimmung des ungebundenen Pharmakons.
Fortbildung für Ärzte. Zentrum für Innere Medizin und Dermatologie, Medizinische Hochschule Hannover, 24.08.1983.
83. Theophylline.
Fortbildungsseminar, Luzern, 12.09.1983.
84. Bioverfügbarkeit von Theophyllin, Proxiphyllin und Diprophyllin in einer oral applizierten Lösung und einem Retard-Präparat.
II. Trommsdorff-Symposium, Lissabon, 07.10.1983.
85. Bestimmung von Digoxin im Serum mittels Immunotests.
Sitzung der Arbeitsgruppe "Drug-Monitoring" der Senatskommission für klinisch-toxikologische Analytik der Deutschen Forschungsgemeinschaft, München, 15.11.1983.
86. Aktuelle Probleme des Drug Monitoring.
Wissenschaftlicher Abend des Zentrallaboratoriums des Allgemeinen Krankenhauses Heidberg, Hamburg, 17.11.1983.
87. Enzymimmunotests zur Schilddrüsen-Diagnostik - Einsatzmöglichkeiten und Zuverlässigkeit.
Fortbildung für Ärzte, Kassel 21.11.1983.
88. Methodik der Enzymimmunotests - Grundlagen, Auswertung, Qualitätskontrolle, Automatisierbarkeit, Einsatzmöglichkeiten.
15. Tagung der Sektion Schilddrüse der Deutschen Gesellschaft für Endokrinologie, Würzburg, 02.12.1983.
Tagungsband: "Wertigkeit von in-vitro-Testverfahren zur Schilddrüsendiagnostik", S. 9-29 (1983).
89. Optimierung der Pharmakotherapie mittels Drug Monitoring.
Fortbildungsveranstaltung für Ärzte, München, 12.12.1983.
90. Therapie mit Theophyllin: Drug Monitoring und Dosisvorhersage.
Veranstaltung des Instituts für Laboratoriumsmedizin des Zentralkrankenhauses St.-Jürgen-Str., Bremen, 14.12.1983.
91. Bestimmung der Proteinbindung von Pharmaka - methodische und klinische Aspekte.
Kolloquium des Zentrums für Laboratoriumsmedizin, Medizinische Hochschule Hannover, Hannover, 25.01.1984.
92. Drug Monitoring und klinische Toxikologie im klinisch-chemischen Laboratorium.
Kolloquium des medizinisch-chemischen Zentrallaboratoriums, Universitätsspital Zürich, Zürich, 09.02.1984.
93. Drug Monitoring - basic concepts.
Seminar, Teheran, 26.02.1984.
94. Drug Monitoring - analytical aspects.
Seminar, Teheran, 26.02.1984.
95. Pharmacokinetics of theophylline.
Symposium: Sustained release theophyllines: factors influencing disposition and therapeutic effect. Köln, 13.04.1984.

96. Probleme des Drug Monitoring.
Symposium für Laboratoriumsdiagnostik der Deutschen Gesellschaft für Laboratoriumsmedizin, Wiesbaden, 11.05.1984.
Abstract: Lab. med. 8, 182, (1984).
97. Bestimmung der Serumkonzentration von Pharmaka zur Therapiekontrolle (Drug Monitoring).
Fortbildungsveranstaltung für Ärzte, Städt. Krankenhaus, Worms, 20.06.1984.
98. Behandlung des Asthma-bronchiale mit Theophyllin unter Berücksichtigung des circadianen Rhythmus.
4. Internationales Symposium über orale Theophylline zur Behandlung obstruktiver Atemwegserkrankungen, London, 28.06.1984.
99. Methylxanthinderivate in der Therapie obstruktiver Atemwegserkrankungen.
Diagnostik- und Therapiekurs "Management of Asthma", Davos, 01.07.-04.07.1984.
100. Determination of theophylline in serum using a highly specific HPLC method.
Diagnostik- und Therapiekurs "Management of Asthma", Davos, 01.07.-04.07.1984.
101. Theophyllin and andere Methyxanthine in der Therapie obstruktiver Ventilationsstörungen.
Kolloquium des Instituts für Klinische Chemie, Medizinische Hochschule Hannover, Hannover, 18.07.1984.
102. Drug Monitoring und Dosisvorhersage bei der Therapie mit Aminoglykosiden.
Fortbildung für Ärzte, Zentrum für Innere Medizin und Dermatologie, Medizinische Hochschule Hannover, Hannover, 22.08.1984.
103. Enzymimmunoassay-Prinzipien und Anwendung.
Kolloquium der Abteilung Gastroenterologie und Hepatologie, Medizinische Hochschule Hannover, Hannover, 06.09.1984.
104. Drug Monitoring und Dosisvorhersage.
Fortbildungsveranstaltung für Ärzte, Städt. Krankenanstalten, Darmstadt, 11.10.1984.
105. Bestimmung von Carbamazepin in Serum und Ultrafiltrat mittels Immunoassay.
Sitzung der Arbeitsgruppe "Drug Monitoring" der Senatskommission für klinisch-toxikologische Analytik der Deutschen Forschungsgemeinschaft, München, 09.11.1984.
106. Entwicklung einer hochspezifischen HPLC-Methode zur Bestimmung von Theophyllin im Serum.
Sitzung der Arbeitsgruppe "Drug Monitoring" der Senatskommission für klinisch-toxikologische Analytik der Deutschen Forschungsgemeinschaft, München, 09.11.1984.
107. Erfahrungsbericht über einen Enzymimmunoassay zur Bestimmung der CK-MB im Serum.
Fortbildung für Ärzte, Zentrum für Innere Medizin und Dermatologie, Medizinische Hochschule Hannover, Hannover, 14.11.1984.

108. Neue Aspekte des Drug Monitoring.
Seminar, Medica 84, Düsseldorf, 21.11.1984.
109. Drug Monitoring und Dosisvorhersage bei der Therapie mit Theophyllin und Aminoglykosiden.
Vortragsreihe "Klinische Biochemie" der Arbeitsgruppe Klinische Chemie am Klinikum der Universität, Freiburg, 13.12.1984.
110. Drug Monitoring-Optimierung der Therapie mit Theophyllin, Aminoglykosiden, Antiepileptika und Kardiaka.
Fortbildungsveranstaltung für Ärzte, Hochgebirgsklinik, Davos-Wolfgang, 14.01.1985.
111. Determination of CK-MB concentration in serum by enzyme immunoassay.
Hybritech Symposium "New Perspectives in CK-MB Parameter", Brüssel, 16.03.1985.
112. Bestimmung von Methotrexat im Serum mittels EMIT und FPIA.
Senatskommission für klinisch-toxikologische Analytik der Deutschen Forschungsgemeinschaft, Arbeitsgruppe "Drug Monitoring", München, 23.04.1985.
113. Bestimmung der Konzentration von Theophyllin und Phenytoin im Speichel und Serumwasser.
Kongreß für Laboratoriumsmedizin, Hamburg, 01.05.1985.
Abstract: Lab. med. 9, 173-174 (1985)
114. Anwendung von pharmakokinetischen Methoden in der Leberfunktionsdiagnostik (Diskussionsbeitrag).
Merck-Symposium 1985, Göttingen, 17.05.1985.
115. Drug Monitoring-Optimierung der Therapie mit Theophyllin, Aminoglykosiden, Antiepileptika und Kardiaka.
1. Badener Meeting, "Drug Monitoring/Virushepatitis", Baden, 29.05.1985.
116. Erfahrungen mit Funktionstesten nach Lebertransplantationen.
Leberbesprechung, Klinik für Abdominal- und Transplantationschirurgie, Medizinische Hochschule Hannover, Hannover, 14.06.1985.
117. Leberfunktionsdiagnostik mittels pharmakokinetischer Methoden.
Fortbildung für Ärzte, Zentrum für Innere Medizin und Dermatologie, Medizinische Hochschule Hannover, Hannover, 28.08.1985.
118. Therapieüberwachung durch Bestimmung der Serumkonzentration am Beispiel von Theophyllin und Digoxin.
37. Therapiekongreß, "Phytopharmakotherapie", Karlsruhe, 02.09.1985.
Abstract: Therapiewoche 35, 50-51 (1985).
119. Optimierung der Pharmakotherapie mittels Drug Monitoring.
Jahrestagung der Österreichischen Gesellschaft für Innere Medizin, Salzburg, 14.09.1985.
120. Drug-Monitoring Therapieüberwachung durch Bestimmung der Serumkonzentration von Pharmaka.
Fortbildungsveranstaltung für Ärzte, Köln, 23.10.1985.

121. Drug Monitoring im Notfalllabor.
Kleinkonferenz der Deutschen Gesellschaft für Klinische Chemie: "Organisation und Management des Notfalllabors - Perspektiven und Aufgaben für die Zukunft".
Hannover, 08.11.1985.
122. Drug Monitoring und Dosisvorhersage bei der Therapie mit Theophyllin.
Seminar: Therapie und Therapiekontrolle. Neue Möglichkeiten des Asthma-Management. Medica 85, Düsseldorf, 23.11.1985.
Abstract: Medica report 6, 129-130 (1985).
123. Drug Monitoring - individuelle Therapiesteuerung durch Bestimmung der Serumkonzentration von Pharmaka.
Ärztliche Fortbildungstagung über "Aktuelle Themen in der Inneren Medizin", Herrliberg-Zürich, 28.11.1985.
124. Anwendung von Immunoassays beim Drug Monitoring - Möglichkeiten und Grenzen.
Sitzung der Arbeitsgruppe "Analytisch technische Entwicklungen" der DFG-Senatskommission für klinisch-toxikologische Analytik. Stuttgart, 28.01.1986.
125. Optimierung der Pharmakotherapie mittels Drug Monitoring.
Fortbildung für Ärzte. Marienhospital Gelsenkirchen, 12.02.1986.
126. Probleme bei der quantitativen Bestimmung von Pharmaka mittels Immunoassays.
Fortbildungsveranstaltung der Gesellschaft für toxikologische und forensische Chemie: "Anwendung immunologischer Methoden in der toxikologischen Analyse".
Bad Vilbel, 21.04.1986.
Abstract: Toxichem. und Krimtech. 42, 5-8 (1986).
127. Interferenzen bei Enzymimmunoassays.
Workshop externe Erprobung ES 600, München, 23.04.1986.
128. Drug Monitoring und Dosisvorhersage.
Theophyllin-Expertenrunde: "Probleme und ihre Lösung bei der Therapie mit Theophyllin", Frankfurt, 25.04.1986.
129. Drug Monitoring-Optimierung der Therapie durch Bestimmung der Serumkonzentration von Pharmaka.
Ärztetage, Labor-Kurs: Fortschritte in der Laboratoriumsdiagnostik. Berlin, 22.05.1986.
130. Dosisvorhersage mittels Drei-Punkt-Methode und einem auf Bayes-Statistik basierenden Rechenprogramm.
10. Sitzung der Arbeitsgruppe "Drug Monitoring", Senatskommission für klinisch-toxikologische Analytik der Deutschen Forschungsgemeinschaft. Hannover, 10.06.1986.
131. Vorhersage der Aminoglykosid- bzw. Theophyllindosis mit einem auf Bayes-Statistik basierenden Rechenprogramm.
Fortbildung für Ärzte, Zentrum für Innere Medizin und Dermatologie. Medizinische Hochschule Hannover, Hannover, 11.06.1986.

132. Theophyllin im Speichel.
Kleinkonferenz der Deutschen Gesellschaft für Klinische Chemie
"Speicheldiagnostik", Bremen, 19.09.1986.
133. Untersuchungen zur Hemmung des mitochondrialen Carnitin-Acylcarnitin-
Translocase Systems.
Vortragsveranstaltung der Universität Gießen, Gießen, 05.11.1986.
134. Leberfunktionsdiagnostik mit Testsubstanzen.
Kolloquium des Instituts für Klinische Chemie, Medizinische Hochschule Hannover,
Hannover, 11.02.1987.
135. Theophyllinkonzentration im Speichel: Stellenwert beim Drug Monitoring.
Fortbildung für Ärzte, Zentrum für Innere Medizin und Dermatologie, Medizinische
Hochschule Hannover, Hannover, 04.03.1987.
136. Theophyllin - eine schwierige Substanz?
III. Kongreß der Deutschen Liga zur Bekämpfung der Atemwegserkrankungen
"Asthma - Bronchitis - Emphysem", München, 14.03.1987.
137. Drug Monitoring - Möglichkeiten und Aussagen.
Fortbildungsveranstaltung des Städtischen Krankenhauses Hildesheim, Hildesheim,
24.03.1987.
138. Leberfunktionsdiagnostik mit Testsubstanzen (ICG, Coffein, Lidocain) im Rahmen
der Lebertransplantation.
Kolloquium der Teilnehmer am DFG-Forschungsprojekt Organtransplantation
Hannover, Medizinische Hochschule Hannover, Hannover, 26.03.1987.
139. Drug Monitoring - Möglichkeiten und Aussage.
dvta Fortbildungskurs, Hamburg, 23.05.1987.
140. Aspekte des Drug Monitoring im A-Labor.
4. Sitzung der Expertengruppe "Toxikologisches A-Labor" der Senatskommission
für klinisch-toxikologische Analytik der Deutschen Forschungsgemeinschaft,
München, 27.05.1987.
141. Fluoreszenz-Polarisations-Immunoassay und immunchemische Teststreifenverfahren.
36. Deutscher Kongreß für ärztliche Fortbildung, Berlin, 10.06.1987.
142. Drug Monitoring - is there a need for standardization?
ECCLS, 8th Annual Conference, Salzburg, 20.06.1987.
143. New developments in clinical chemistry: Bayesian forecasting, MEGX formation
kinetics as a test of liver function, ciclosporin monitoring.
Seminar, Abbott Laboratories, Dallas (Irving), 08.-09.07.1987.
144. Leberfunktionsdiagnostik mittels Lidocaintest.
Fortbildung für Ärzte, Zentrum für Innere Medizin und Dermatologie, Medizinische
Hochschule Hannover, Hannover, 02.09.1987.
145. A novel approach to assessment of liver function in donors.
International Organ Transplant Forum, Pittsburgh, 08.-10.09.1987.

146. Anwendung der Bayes-Statistik bei der Vorhersage des individuellen Serumkonzentrationsverlaufes von Pharmaka.
Symposium: Klinisch-toxikologische Analytik bei akuten Vergiftungen und Drogenmißbrauch. Salzburg, 16.09.1987.
Abstract: J. Clin. Chem. Clin. Biochem. 25, 622-623 (1987).
147. Drug Monitoring: Neue Verfahren zur individuellen Therapiesteuerung.
Theophyllin Workshop, Karl-Hansen-Klinik, Bad Lippspringe, 01.10.1987.
148. Experience with quantitative liver function tests based on MEGX formation or caffeine clearance.
Seminar, Abbott Laboratories, North Chicago, 26.10.1987.
149. Quantitative liver function tests in liver transplantation.
Special Seminar. The University of Chicago, Department of Surgery, Chicago, 26.10.1987.
150. Experience with immunosticks and liver function tests.
Seminar, Syva, Palo Alto, 28.-29.10.1987.
151. Clinical experience with Bayesian drug dosing programs for theophylline and aminoglycosides.
Conference of the German Society for Clinical Chemistry "Bayesian forecasting - application in therapeutic drug monitoring". Hannover, 06.11.1987.
152. Inhibition of guinea pig liver carnitine acylcarnitine translocase by 2-(3-methylcinnamyl-hydrazono)-propionate and a structurally related hypoglycaemic compound.
European Association for the Study of Diabetes (EASD). Meeting of the study group "Control of Metabolism", Brüssel, 21.11.1987.
153. Influence of hypoglycemic substances on the glucose fatty acid cycle in lymphocytes.
European Association for the Study of Diabetes (EASD). Meeting of the study group "Control of Metabolism", Brüssel, 21.11.1987.
154. MEGX-Bildungskinetik zur Beurteilung der Leberfunktion.
Gastroenterologisches Kolloquium, Medizinische Hochschule Hannover, Hannover, 03.12.1987.
155. Kinetik der Bildung von Monoethylglycinxylylid: Ein neues Verfahren zur Leberfunktionsprüfung.
Vortragsveranstaltung der Universität Hamburg, Hamburg, 29.01.1988.
156. Evaluation von quantitativen Leberfunktionstests (MEGX-, Coffein-, ICG-Test) bei lebertransplantierten Patienten.
4. Tagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber (GASL). Berlin, 30.01.1988.
Abstract: Z. Gastroenterologie 26, 56-57 (1988).
157. Drug Monitoring und Bayes-Verfahren zur individuellen Therapiesteuerung.
Internistenkongreß, Satellitensymposium: Ein neues Atemwegstherapeutikum stellt sich vor. Wiesbaden, 12.04.1988.

158. Acetoacetat/3-Hydroxybutyrat Quotient und MEGX-Bildung bei lebertransplantierten Patienten.
Kolloquium der Forschergruppe Organtransplantation, Hannover, 03.05.1988.
159. Neuere Aspekte der Leberfunktionsdiagnostik.
2. Norddeutsches Gespräch in Klinischer Chemie., Wilhelmshaven, 07.05.1988.
160. Neuere Entwicklungen bei der Mechanisierung immunchemischer Verfahren.
Jahrestagung der Österreichischen Gesellschaft für Laboratoriumsmedizin, Bad Ischl, 09.06.1988.
161. Donor rating in human liver transplantation: correlation of oxygen consumption after revascularization with MEGX formation in donors.
XII International Congress of the Transplantation Society, Sydney, 18.08.1988.
162. Evaluation eines Bayes-Verfahrens zur Vorhersage der Vancomycin-Konzentration im Serum.
Fortbildung für Ärzte, Zentrum für Innere Medizin und Dermatologie, Medizinische Hochschule Hannover, Hannover, 31.08.1988.
163. Basic concepts of pharmacokinetics.
7th Congress of the European Society of Pneumology. Microbiology-pharmacology scientific section meeting, Budapest, 09.09.1988.
164. MEGX formation test in liver transplantation.
Kinderklinik, Medizinische Hochschule Hannover, Hannover, 25.10.1988.
165. Sources of errors in different protein binding assay systems. Pharmacology and toxicology.
IFCC Master Discussions. The Bergmeyer Conferences. Improvement of comparability and compatibility of laboratory assay results in life sciences. 1. Conference. Principles of assay results in life sciences. Bad Tölz, 01.11.1988.
166. Efficiency of the MEGX formation test in liver transplantation.
39th Annual Meeting of the American Association for the Study of Liver Diseases. Update on Hepatic Transplantation. Chicago, 05.11.1988.
Abstract: Hepatology 8, 1220 (1988).
167. Utility of MEGX with liver transplantation.
Special Seminar: Current and future trends in liver function testing. Chicago, 05.11.1988.
168. Clinical experience with the MEGX liver function test in transplantation.
Seminar. The University of Chicago. Department of Surgery. Chicago, 08.11.1988.
169. Experience with the Ektachem 700 and liver function tests.
Seminar, Kodak, Rochester, 09.11.1988.
170. Inhibition of mitochondrial carnitine acylcarnitine translocase by hypoglycaemic substances.
Workshop conference on carnitine. Organized by the Austrian and German Society for Clinical Chemistry. Wien, 04.12.1988.

171. Therapeutic drug monitoring: Basic concepts and novel approaches for dosage prediction.
Symposium on poisoning in the community. Dammam, Saudi Arabia, 08.12.1988.
172. Prognostische Wertigkeit des MEGX-Tests bei Transplantations-Kandidaten und lebertransplantierten Patienten.
5. Tagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber (GASL), Düsseldorf, 20.01.1989.
Abstract: Z. Gastroenterol., 27, 50-51 (1989).
173. Neues auf dem Gebiet der Leberfunktionsdiagnostik.
4. Jahrestagung der Gesellschaft für Pädiatrische Gastroenterologie und Ernährung (GPGE '89), Goslar, 03.03.1989.
174. Prognostische Bedeutung des MEGX-Tests auf dem Gebiet der Lebertransplantation.
Kolloquium des Instituts für Klinische Chemie, Medizinische Hochschule Hannover, Hannover, 12.04.1989.
175. Dosisvorhersage mit pharmakokinetischen Methoden.
Seminar zur Weiterbildung für Klinische Chemiker. Hannover, 27.05.1989.
176. Lidocaine metabolite formation as a measure of pre- and posttransplant liver function.
Gemeinsames Treffen der Lebertransplantationsgruppen Cambridge und Hannover, Hannover 19.06.1989.
177. MEGX formation as a measure of liver function in donors and liver recipients.
Seminar. University of Cincinnati Medical Center, Cincinnati, 20.07.1989.
178. MEGX formation: A novel approach for assessment of liver function in donors and liver recipients.
41st National Meeting of the American Association for Clinical Chemistry.
Workshop: "Transplant Diagnostics", Atlanta, 25.07.1989.
179. Prognostic value of the MEGX liver function test in transplant candidates.
41st National Meeting of the American Association for Clinical Chemistry. Atlanta, 26.07.1989.
Abstract: Clin. Chem. 35, 1135 (1989).
180. Assessment of short-term prognosis in transplant candidates with cirrhosis.
24th Meeting of the European Association for the Study of the Liver. München, 31.08.1989.
Abstract: J. Hepatol. 9, (Suppl. 1), 67 (1989).
181. Ermittlung der kurzfristigen Prognose von Transplantations-Kandidaten mit Hilfe von Leberfunktionstests.
Fortbildung für Ärzte, Zentrum für Innere Medizin und Dermatologie, Medizinische Hochschule Hannover, Hannover, 06.09.1989.
182. Drug Monitoring - pharmakokinetische Grundlagen.
Arbeitstagung: Asthma bronchiale "Ideale Therapie - durchführbare Therapie", anlässlich: XIVth Congress of the European Academy of Allergology and Clinical Immunology, Berlin, 17.09.1989.

183. Prognostische Sensitivität und Spezifität des MEGX Leberfunktionstests bei Transplantations-Kandidaten.
Jahrestagung der Deutschen Gesellschaft für Klinische Chemie, Berlin, 11.10.1989.
Abstract: J. Clin. Chem. Clin. Biochem. 27, 757 (1989).
184. Experience with the MEGX test in clinical liver transplantation.
Fortbildungsseminar, Wiesbaden, 16.10.1989.
185. Lidocaine metabolite formation: a novel approach for assessment of liver function in hepatic transplantation.
Seminar. The Cleveland Clinic Foundation, Cleveland, 26.10.1989.
186. Development and clinical application of the MEGX liver function test.
Press conference, Chicago, 30.10.1989.
187. Lidocaine metabolite formation as a measure of early posttransplant liver function.
40th Annual Meeting of the American Association for the Study of Liver Diseases, Chicago, 31.10.1989.
Abstract: Hepatology 10, 625 (1989).
188. 2-(3-Phenylpropoxyimino)-butyric acid, a novel hypoglycaemic substance. Effects on glucose and fatty acid oxidation in the isolated rat hemidiaphragm using ¹⁴C-labelled substrates.
European Association for the Study of Diabetes (EASD). Meeting of the study group "Control of Metabolism", London, 03.11.1989.
189. Einsatz von Methoden zur Dosisvorhersage und pharmakokinetische Grundlagen des Drug Monitoring.
Fortbildungsveranstaltung für Ärzte, Wiesbaden, 06.12.1989.
190. Klinisch-chemische Funktionsdiagnostik am Beispiel der Leberfunktionsprüfung bei Transplantations-Kandidaten.
Vortragsveranstaltung der Universität Göttingen, Göttingen, 11.01.1990.
191. Prognostische Wertigkeit von Leberfunktionstesten und klinischen Befunden bei pädiatrischen Transplantationskandidaten.
6. Tagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber (GASL), Bonn, 27.01.1990.
Abstract: Z. Gastroenterol. 28, 73 (1990).
192. Drug Monitoring: Pharmakokinetische Grundlagen und Methoden zur Dosisvorhersage.
Seminar, Kinderklinik, Medizinische Hochschule Hannover, Hannover, 02.05.1990.
193. Flucytosine: Determination in serum by HPLC and dosage individualization.
Analytica 90, München, 09.05.1990.
194. Free radical scavenging enzyme activities in erythrocytes of pediatric patients with Crohn's disease.
Trends in inflammatory bowel disease therapy, Halifax, 07.06.1990.
195. Assessment of liver function in donors by use of the MEGX test.
International Symposium on Artificial Liver Support, Celle, 18.06.1990.

196. Lidocaine metabolite formation as a prognostic indicator in transplant candidates with cirrhosis.
XIV International Congress of Clinical Chemistry, San Francisco, 26.07.1990.
Abstract: Clin. Chem. 36, 1170 (1990).
197. Functional state of the donor liver and early outcome of transplantation.
XIII International Congress of the Transplantation Society, San Francisco, 22.08.1990.
198. Lidocaine metabolism review.
European Liver Club meeting, Cambridge, 08.09.1990.
199. Drug metabolism as index of liver function.
2nd International Congress of Therapeutic Drug Monitoring and Toxicology, Barcelona, 11.10.1990.
Abstract: Quimica Clinica 9, 314 (1990).
200. Lidocaine metabolite formation as an indicator of liver function in donors and recipients.
2nd International Congress of Therapeutic Drug Monitoring and Toxicology.
Workshop: "Using TDM to measure organ function". Barcelona, 12.10.1990.
201. Predictors of early outcome of liver transplantation.
Workshop: "MEGX", Chicago, 03.11.1990.
202. Predictors of one-year survival in pediatric liver cirrhosis.
41st Annual Meeting of the American Association for the Study of Liver Diseases, Chicago, 04.11.1990.
Abstract: Hepatology 12, 858 (1990).
203. MEGX formation as a measure of liver function in clinical transplantation.
Seminar, Mailand, 16.11.1990.
204. Pharmakokinetische Grundlagen des Drug Monitoring und der individuellen Dosisanpassung.
11. Symposium der Chirurgischen Arbeitsgemeinschaft für Intensiv- und Notfallmedizin der Deutschen Gesellschaft für Chirurgie, Köln, 06.12.1990.
205. Leberfunktionsdiagnostik mittels MEGX-Test.
Kolloquium des Medizinisch-chemischen Zentrallaboratoriums, Universitätsspital Zürich, Zürich, 11.12.1990.
206. Aktivität der Radikalfängerenzyme in Erythrozyten bei Patienten mit Morbus Crohn.
Seminar: Radikalsysteme im Rahmen entzündlicher Erkrankungen, Scavenger-Enzyme. Kinderklinik, Medizinische Hochschule Hannover, Hannover, 25.01.1991.
207. Funktionsdiagnostik in der Lebertransplantation: Prognostische Aussagen klinisch-chemischer Methoden.
Antrittsvorlesung, Georg-August-Universität Göttingen, Göttingen, 12.06.1991.
208. MEGX formation as an indicator of liver function.
Tavola rotonda: "MEGX: indicatore di funzione epatica nei pazienti a rischio".
Mailand, 02.07.1991.

209. Donor rating and assessment of pretransplant prognosis by use of the MEGX test. International Symposium on Drugs and the Liver. High Risk Patients and Transplantation. Fondazione Giovanni Lorenzini, Mailand 03.07.1991.
210. Drug metabolism as an indicator liver function. 43rd National Meeting of the American Association for Clinical Chemistry. Selected topics section, Washington, 30.07.1991.
211. Assessment of donor organ function. 26th Meeting of the European Association for the Study of the Liver. International Symposium on Liver Transplantation, Palma de Mallorca, 11.09.1991.
212. Drug Monitoring. 5. Treffen der Hauptamtlichen Laborleiter der Krankenhäuser in Nordrhein-Westfalen, Dortmund, 04.10.1991.
213. Drug monitoring. 23. Gemeinsame Jahrestagung der Deutschen Gesellschaft für Internistische Intensiv- und Notfallmedizin und der Österreichischen Gesellschaft für Internistische und allgemeine Intensivmedizin. Stammtischrunden, Hannover, 24.10.1991.
214. MEGX formation - a novel approach for the assessment of liver function. Seminar, St. Jude Children's Research Hospital, Memphis, 01.11.1991.
215. New aspects of therapeutic drug monitoring. Round Table: Present developments and future trends in photometry. Düsseldorf, 22.11.1991.
216. Drug Monitoring - Methoden zur Dosisvorhersage. Internistenfortbildung, Göttingen, 10.12.1991.
217. Prognostische Wertigkeit der Kombination von Pugh-Score und MEGX-Test bei Lebertransplantations-Kandidaten. 8. Tagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber (GASL). Marburg, 24.01.1992. Abstract: Z. Gastroenterol. 30, 74 (1992).
218. Gegenwärtiger Stand der MEGX-Diagnostik. Symposium: Ciclosporin Monitoring und Leberfunktionsdiag-nostik mit dem MEGX-Test. Wiesbaden, 25.02.1992.
219. Assessment of liver function in donors and recipients. Lecture. Plenary session: Assessment of graft function. Liver intensive care group of Europe (LICAGE) 5th Meeting. Rom, 04.04.1992.
220. Probleme des Drug Monitoring bei der Kombinationstherapie. Symposium der Arzneimittelkommission der Deutschen Ärzteschaft: "Kombinationstherapie - sinnvoll, überflüssig, gefährlich? Wiesbaden, 26.04.1992.

221. Bedeutung des Drug Monitoring in der Intensivmedizin
Anaesthesiologisches Kolloquium, Georg-August-Universität, Göttingen. Göttingen,
12.05.1992.
222. Neue Aspekte des Drug Monitoring.
Seminar: "Medizinische Laboratoriumsdiagnostik". Tutzing, 14.05.1992.
223. Current status of the use of liver function tests in transplantation.
III Simposio Nazionale Monitoraggio Farmaci e Droghe d'Abuso. Florenz,
23.06.1992.
224. Leberfunktionsdiagnostik mittels MEGX-Test.
Internistenfortbildung, Göttingen, 30.06.1992.
225. Assessment of prognosis in transplant candidates by use of the Pugh-MEGX score.
XIVth International Congress of the Transplantation Society. Paris, 20.08.1992.
226. Valutazione della funzione del trapianto.
XIII Congresso Nazionale S.I.P.A.D, Tavola Rotonda: Problematiche dei Trapianti
Epatico e Pancreatico. Perugia, 11.09.1992.
226. Use of drugs to assess liver function.
8e Colloque International de Pont-à-Mousson, Biologie Prospective. Metz,
17.09.1992.
227. Drug Monitoring.
Klinisch-chemisches Kolloquium, Wuppertal, 14.10.1992.
228. Leberfunktionsdiagnostik mittels MEGX-Test.
Klinisch-chemisches Kolloquium, Berlin, 22.10.1992.
229. Role of carbamazepine determination in the TDM concept.
Meeting CEDIA Carbamazepine multicentre evaluation. Deidesheim, 27.10.1992.
230. Lidocaine metabolite formation as a measure of liver function in ICU-patients.
International Symposium of the Belgian Society of Intensive Care and Emergency
Medicine. Gent, 06.11.1992.
231. Drug Monitoring: Pharmakokinetische Grundlagen, Methoden, Interpretation.
Fortbildungsveranstaltung, Nörten Hardenberg, 08.12.1992.
232. Assessment of early posttransplant liver function.
Recent Advances in Pathology Symposium. Riad, 13.12.1992.
233. Use of drugs to assess liver function.
Recent Advances in Pathology Symposium. Riad, 14.12.1992.
234. Problems of immunosuppressive drug monitoring.
3rd International Congress of Therapeutic Drug Monitoring and Clinical Toxicology.
Workshop: "Practical aspects of immunosuppressive drug monitoring". Philadelphia,
26.05.1993.
235. Use of drugs for organ-function testing in clinical transplantation.
3rd International Congress of Therapeutic Drug Monitoring and Clinical Toxicology.
Breakfast Roundtable. Philadelphia, 27.05.1993.

236. Drug Monitoring bei der Therapie mit Immunsuppressiva.
Internistenfortbildung, Göttingen, 15.06.1993.
237. Einfluß der Lipidperoxidation auf Struktur und Aktivität von Cytochrom P-450 IIIA der Rattenleber.
Kolloquium SFB 330, Teilprojekt D8, Göttingen, 24.06.1993.
238. Leberfunktionsdiagnostik mit dem MEGX-Test.
Endokrinologisches und Stoffwechsel-Kolloquium der Abt. Innere Medizin IV,
Eberhard-Karls-Universität Tübingen, Tübingen, 07.07.1993.
239. Current concept in assessing pretransplant liver disease by dynamic liver function tests.
International Symposium. Frontiers in transplantation and medical treatment of liver diseases. Hamburg, 11.09.1993.
240. Metabolic influences on the response to immunosuppressive drugs.
Monitoring Immunosuppressive Therapy: Cyclosporin and Beyond. London,
08.10.1993.
241. Assessment of pretransplant liver disease by dynamic liver function tests.
Milwaukee, Medical College of Wisconsin, Dept. of Pathology, 03.11.1993.
242. Supplementation of organ preservation solutions with idebenone (QSA-10) protects liver microsomes against oxygen-radical-mediated damage.
44th Annual Meeting of the American Association for the Study of Liver Diseases,
Chicago, 4-7 November 1993.
243. Pharmacokinetics and monitoring of antimycotic drugs.
International Workshop, Systemic Fungal Infections. Göttingen, 20.11.1993.
244. Valproinsäure. Erprobungstreffen CEDIA Valproinsäure, Multicenter-Studie.
Bad Dürkheim, 20.05.1994.
245. QSA 10 (Idebenone) or probucol supplementation of organ preservation solutions prevents oxygen radical mediated injury of hepatic microsomes.
XVth World Congress of the Transplantation Society, Kyoto, 01.09.1994.
246. Assessment of liver disease by dynamic liver function tests.
Peking, Beijing Hospital, 05.09.94.
247. Leberfunktionsteste in der Diagnostik von Transplantat-dysfunktion.
Seminar: Diagnostische Profile in der prä- und postoperativen Phase der Transplantationsmedizin. Kongreß für Laboratoriumsmedizin, Berlin, 27.09.94.
248. Lebertransplantation: Funktionsdiagnostik bei Transplantationskandidaten und im postoperativen Verlauf.
Merck-Symposium der Deutschen Gesellschaft für Klinische Chemie:
"Pathobiochemie und klinisch-chemische Diagnostik der Transplantation von Zellen und Organen". Bad Oeynhausen, 20.10.1994

249. Prediction of early graft survival and complications by serial determination of MEGX and hyaluronic acid after OLT.
45th Annual Meeting of the American Association for the Study of Liver Diseases, Chicago, 12.11.1994.
250. Cyclosporin A - Introduction.
International Consensus Conference on Immunosuppressive Drugs. Chateau Lake Louise, Lake Louise Alberta, Canada, 06.05.1995.
251. Assessment of prognosis in transplant candidates and monitoring of hepatic metabolic function in liver recipients.
ESPGAN Hepatology Summer School 1995. Wilsede, 06.07.1995.
252. Cyclosporin A. Immunosuppressive Drug Monitoring - A report of the Consensus Meeting.
4th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology. Vienna, 05.09.1995.
253. Cyclosporin and tacrolimus monitoring: Specificity requirements.
Abbott Laboratories, Abbott Park, Illinois, USA, 03.11.1995.
254. Heat-shock protein 70 gene expression in a pig liver cold ischemia/reperfusion model: influence of storage time and gadolinium chloride.
46th Annual Meeting of the American Association for the Study of Liver Diseases, Chicago, 05.11.1995.
255. Assessment of liver function by the use of MEGX- and ICG-tests.
1. Internationales Jenaer Symposium „Theorie und Praxis der Anaesthesiologie und Intensivmedizin“ Aktuelle Konzepte und Perspektiven zur Überwachung und Diagnose von kritisch Kranken. Jena, 26.01.1996.
Abstract: Clinical Intensive Care 1996; Suppl, 7: 29-30.
256. Expression von HSP70, c-fos, TNF-alpha und iNOS mRNA in einem Schweineleberperfusionsmodell: Einfluß der kalten Ischämie in HTK-Organprotektionslösung.
12. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber (GASL). Hamburg, 26.01.1996.
Abstract: Z Gastroenterol 33, 74 (1996).
257. Drug Monitoring von Immunsuppressiva.
10. Norddeutsches Gespräch in Klinischer Chemie. Göttingen, 03.03.1996
258. Klinisch-chemische Forschung im Spannungsfeld zwischen Medizin und Naturwissenschaften
Grußwort anlässlich der Emeritierung von Herrn Prof. Dr. Dr. J. Büttner. Medizinische Hochschule Hannover, Hannover, 08.03.1996.
Abstract: DG Klinische Chemie Mitteilungen 1996;27:55-59.

259. Stellenwert des MEGX-Tests in der Leberfunktionsdiagnostik.
Symposium: Klinisch-chemische Forschung im Spannungsfeld zwischen Medizin und Naturwissenschaften. Medizinische Hochschule Hannover. Hannover 09.03.1996.
Abstract: DG Klinische Chemie Mitteilungen 1996; 27:68-69.
260. Immunosuppressive drug monitoring in transplantation.
Overview of current and planned drugs. Colloquium: Drug monitoring in transplantation. XVI International Congress of Clinical Chemistry. London, 10.07.96
261. Cyclosporine in Organ Transplantation.
3rd Jerusalem Conference on Pharmaceutical Sciences and Clinical Pharmacology - JC. Jerusalem, 04.09.1996
262. Evaluation of the EMIT mycophenolic acid assay - comparison with an HPLC procedure.
49th Annual meeting & clinical laboratory exposition AACC EduTrak program. Atlanta, 22.07.1997.
263. Analytical and clinical aspects of azathioprine and mycophenolic acid monitoring.
Seminar Philadelphia, 24.07.1997.
264. Clinical and analytical aspects of MPA determination in transplant patients.
Progress in Transplantation Medicine. Research, Laboratory Monitoring and Clinical Perspectives. Nizza, 23.10.1997.
265. Therapeutic drug monitoring of cyclosporine and tacrolimus.
5th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology. Vancouver, 12.11.1997.
266. Drug Monitoring von Immunsuppressiva.
Wissenschaftliches Symposium: Ausblicke für die Kinderheilkunde anlässlich des 65. Geburtstages von Herrn Professor Dr.med. W. Schröter. Arolsen, 17.07.1998.
267. Newly detected MPA metabolites and their inhibitory effect on IMPDH.
Seminar, Dade Behring. San José, 29.07.1998.
268. Newly detected MPA metabolites and their inhibitory effect on IMPDH.
Dade Behring Workshop: "Should MPA Monitoring become a common medical practice". 50th Annual meeting & clinical laboratory exposition AACC. Chicago, 04.08.1998.
269. Drug monitoring of immunosuppressants.
International Symposium: "Laboratory diagnostics and drug therapy", Sechenov Medical Academy. Moskau, 10.09.1998.
270. Lidocaine metabolism as an index of liver function.
Symposium: 6th International Meeting of the Balkan Clinical Laboratory Federation. Plovdiv, 10.10.1998.

271. Assessment of liver function by use of dynamic tests.
Bulgarian National Academy of Medicine. Sofia, 12.10.1998.
272. Leberfunktionsdiagnostik mittels MEGX-Test im Rahmen der Transplantation,
Intensivmedizin und Onkologie.
Kolloquium Jena, 24.11.1998.
273. Ist das Drug Monitoring für Mycophenolsäure klinisch sinnvoll?
Seminar Ulm, 26.11.1998.
274. Dynamic tests in assessment of liver function.
Symposium: Monitoring of therapeutic drugs in clinical practice. I.M. Sechenov
Moscow Medical Academy. Moskau, 21.05.1999.
275. Dynamic tests in assessment of liver function.
University of Alberta, Seminar. Edmonton, 23.07.1999.
276. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric
renal transplant recipients: implications for therapeutic drug monitoring.
Symposium: Immunosuppressant Drugs –3, Mycophenolate Mofetil. 6th International
Congress of Therapeutic Drug Monitoring and Clinical Toxicology. Cairns,
17.09.1999.
277. Assessment of liver function by a rapid dynamic test.
Annual scientific conference of the Vietnamese Association of Clinical Biochemists
(VACB) in collaboration with IATDMCT and the 9th MASEAN conference. Hanoi,
29.10.1999.
278. Pharmacokinetic and clinical outcome data of total and free mycophenolic acid in
pediatric renal transplant recipients.
Global Roundtable: Current issues in therapeutic drug monitoring of mycophenolic
acid. Nizza, 03.12.1999.
279. Drug Monitoring von Mycophenolsäure.
Transplantationskonferenz. Göttingen, 22.02.2000.
280. Biomarkers of hepatic disease.
Plenary session: Biomarkers of hepatic and gastrointestinal diseases. European
meeting on biomarkers of organ damage and dysfunction. Embury 2000. Cambridge,
05.04.2000.
281. Drug Monitoring von Immunsuppressiva nach Nierentransplantation.
Stuttgarter Transplantationsseminar 2000 (Katharinenhospital). Stuttgart,
11.05.2000.
282. C₂-Monitoring of Cyclosporin.
Seminar, Dade Behring. San José, 28.07.2000.

283. Therapeutic drug monitoring of cyclosporin and tacrolimus in transplant patients – progress and pitfalls.
Symposium: Advances in the science and practice of therapeutic drug monitoring and clinical toxicology. Konferencja Naukowo-Szkoleniowa Polskiego Towarzystwa Diagnostyki Laboratoryjnej (in collaboration with IATDMCT). Warsaw, 21.09.2000.
284. Therapeutic drug monitoring of mycophenolic acid and tacrolimus without steroids.
Seminar: Current issues in therapeutic drug monitoring of mycophenolic acid. München, 26.10.2000.
285. MPA monitoring – issues and questions.
Seminar: Current issues in therapeutic drug monitoring of mycophenolic acid. München, 26.10.2000.
286. Creeping creatinine pharmacokinetic study interim results.
Investigator Meeting: M 55012 "Creeping creatinine" study. Malaga, 24.11.2000.
287. Blutspiegelmonitoring bei Rapamune® (Sirolimus).
Workshop: Rapamune® (Sirolimus). Dokumentation der klinischen Erfahrungen. Berlin, 03.03.2001.
288. MPA acylglucuronide.
Roche Discovery Welwyn. Welwyn Garden City, 07.03.2001.
289. Mycophenolic acid monitoring in pediatric kidney transplant recipients, analytical and QC problems.
8th International Congress on Pediatric Laboratory Medicine. Symposium: Challenges of transplantation in children. Cairo, 17.03.2001.
290. Metabolic and pharmacokinetic aspects of TDM.
Conference on Molecular Biology and Biochemistry of the Vietnamese Association of Clinical Biochemists (VACB). Ho Chi Minh City, 25.06.2001
291. Two-hour cyclosporine concentration determination: an appropriate tool to monitor Neoral therapy?
7th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology. Symposium: Immunosuppressant therapeutic drug monitoring: new paradigms. Washington D.C., 05.09.2001.
292. Creeping creatinine pharmacokinetic study results.
M 55012 "Creeping Creatinine" Study Investigators' Meeting. Lissabon, 07.10.2001.
293. Drug Monitoring von Immunsuppressiva.
13. Transplantationskolloquium, Transplantationszentrum Gießen. Gießen, 04.12.2001.
294. MMF – Pharmakokinetik und Drug Monitoring.
5. Basler Transplantationsgespräch, Hoffmann-La Roche AG. Basel 16.03.2002.

295. Azathioprine therapy: do we need genotyping or phenotyping?
Avances en el estudio de drogas tóxicas y terapéuticas. Un simposium internacional bajo los auspicios de IATDMCT. Santiago, 18.04.2002.
296. Drug Monitoring von Immunsuppressiva.
3. Kolloquium des Instituts für Laboratoriumsmedizin, Klinische Chemie und Molekulare Diagnostik (ILM), Universitätsklinikum Leipzig. Leipzig, Germany, 06.05.2002.
297. Drug Monitoring von Immunsuppressiva.
Kolloquium Klinische Chemie und Laboratoriumsmedizin. Jena, 07.05.2002.
298. Pharmacokinetics and metabolic investigations of mycophenolic acid in transplant recipients.
CSCC Travelling Lectureship 2002, Transplantation Grand Rounds. Joint Scientific Meeting. Halifax, Canada, 20.09.2002.
299. Analytical and clinical aspects of monitoring immunosuppressive therapy with mycophenolic acid, sirolimus and everolimus.
CSCC Travelling Lectureship 2002, Immunosuppressive Drugs in Transplantation. London (Ontario), Canada, 23.09.2002.
300. Azathioprine: Do we need genotyping or phenotyping?
CSCC Travelling Lectureship 2002, Mini-Symposium Therapeutic Drug Monitoring. Toronto, Canada, 24.09.2002.
301. Pharmacokinetics and metabolic investigations of mycophenolic acid in transplant recipients.
CSCC Travelling Lectureship 2002, Laboratory support to immunosuppressive drug monitoring – current and future trends. Ottawa, Canada, 25.09.2002.
302. Analytical and clinical aspects of monitoring immunosuppressive therapy with sirolimus and everolimus.
Laboratory support to immunosuppressive drug monitoring – current and future trends. Ottawa, Canada, 25.09.2002.
303. Real-time assessment of hepatic function in pre-transplantation liver disease and critically ill patients.
CSCC Travelling Lectureship 2002, Congres Annuel 2002 de l'AMBQ. Montebello, Canada, 26.09.2002.
304. Azathioprine therapy: do we need to genotyping or phenotyping?
CSCC Travelling Lectureship 2002, Congrès Annuel 2002 de l'AMBQ. Montebello, Canada, 26.09.2002.
305. Analytical and clinical aspects of monitoring immunosuppressive therapy with mycophenolic acid, sirolimus and everolimus.
CSCC Travelling Lectureship 2002, Special Lecture, Saskatoon, Canada, 30.09.2002.

306. Should cyclosporine 2 hour post-dose levels become the preferred pharmacokinetic parameter to monitor Neoral therapy?
CSCC Travelling Lectureship 2002, Special Lecture. Saskatoon, Canada, 30.09.2002.
307. Pharmacokinetics and metabolic investigations of mycophenolic acid in transplant recipients. Investigations in immunosuppressive drug therapy. CSCC Travelling Lectureship 2002, Vancouver, Canada, 02.10.2002.
308. Real-time assessment of hepatic function in pre-transplantation liver disease and critically ill patients.
CSCC Travelling Lectureship 2002, Jasper, Canada, 05.10.2002.
309. Thiopurine methyltransferase: do we need to genotype, phenotype or both to optimise azathioprine therapy?
Symposium: New paradigms for therapeutic drug monitoring of immunosuppressive drugs. 18th International Congress of Clinical Chemistry and Laboratory Medicine; Kyoto, Japan, 23.10.2002.
310. Pharmacokinetics and metabolic investigations of mycophenolic acid in transplant recipients.
Symposium: Consolidamento e integrazione del Laboratorio Clinico: Dai Modelli Teorici alla Realizzazione pratica. 16° Congresso Nazionale Società Italiana di Medicina di Laboratorio, Milan, Italy, 28.11.2002.
311. The clinical laboratory organisation model in Germany.
Symposium: L'Organizzazione dei Servizi di Medicina di Laboratorio in Europa. 16° Congresso Nazionale Società Italiana di Medicina di Laboratorio, Milan, Italy, 29.11.2002.
312. Klinische und analytische Aspekte des Drug Monitoring von Immunsuppressiva.
Erstes Seminar der Akademie für Transplantationsimmunologie, Berlin, Germany, 06.12.2002.
313. Genotypic and phenotypic evaluations in connection with azathioprine toxicity.
Symposium: Understanding mechanisms of toxicity of immunosuppressive drugs to improve their safety profiles and broaden the scope of their use. Society of Toxicology. 42nd Annual Meeting. Salt Lake City, USA, 10.03.2003.
314. Blutspiegelmonitoring bei Sirolimus, Pharmakokinetik und Einfluss von Komedikation.
Workshop: Immunsuppression bei herztransplantierten Patienten in der Langzeittherapie. Standortbestimmung und Perspektiven. München, Germany, 17.05.2003.
315. Analytical and clinical aspects of monitoring sirolimus, everolimus and C₂-cyclosporine concentrations.
Symposium: Advances in therapeutic drug monitoring in organ transplantation. EUROMEDLAB 2003. Barcelona, Spain, 04.06.2003.

316. Impact of pharmacogenetics on immunosuppressive drug monitoring. Symposium: TDM and pharmacogenomics. 22nd World Congress of Pathology & Laboratory Medicine (WASPaLM). Busan, South Korea, 01.09.2003.
317. Immunosuppressive drug monitoring in pediatric patients. Symposium: Toxicology / Therapeutic Drug Monitoring. IXth International Congress of Pediatric Laboratory Medicine. Rom, Italy, 14.09.2003.
318. Drug Monitoring von Immunsuppressiva. 17. Treffen der hauptamtlichen Laborleiter der Krankenhäuser in Nordrhein-Westfalen. Bochum, Germany, 17.10.2003.
319. Drug Monitoring – LC/MS-MS Analytik und Pharmakogenetik von Immunsuppressiva. Symposium: „Therapeutisches Drug Management“. Frankfurt, Germany, 15.01.2004.
320. Recent advances in therapeutic drug monitoring. Keynote Address. Inaugural Session, Laboratory Medicine Conference. Medicare India, New Delhi, 06.04.2004.
321. Steuerung der Therapie mit Azathioprin anhand der erythrozytären TPMT-Aktivität und der 6-Thioguaninnukleotide. Symposium Hauptthema 4: „Kontroversen und Zukunft der interdisziplinären Therapie“. 13. Kongress der Mitteldeutschen Gesellschaft für Gastroenterologie. Suhl, Germany, 08.05.04.
322. Potential mechanisms for side effects under mycophenolate mofetil therapy. GI complications in transplantation - Experts' Meeting. Boston, USA, 14.05.2004.
323. Immunosuppressive drug monitoring. Seminar, Roche Diagnostics, Indianapolis, USA, 30.07.2004.
324. Impact of pharmacogenetics on therapeutic drug monitoring. Seminar, Roche Diagnostics, Indianapolis, USA, 30.07.2004.
325. FDCC-study: interim report on free MPA and AcMPAG in renal transplant recipients. FDCC steering committee meeting. Wien, Austria, 05.09.2004.
326. Impact of pharmacogenetics on therapeutic drug monitoring. APCC Congress. Perth, Australia, 20.09.2004.
327. Methodological aspects of LC-MS/MS in TDM. PathCentre Perth. Perth, Australia, 27.09.2004.
328. Monitoring strategies in immunosuppressive drug monitoring. PathCentre Perth. Perth, Australia, 27.09.2004.
329. Potential mechanism for side effects under mycophenolate mofetil therapy. PathCentre Perth. Perth, Australia, 27.09.2004.

330. Clinical aspects of monitoring immunosuppressive therapy with mycophenolic acid, sirolimus and everolimus.
PathCentre Perth. Perth, Australia, 28.09.2004.
331. Mycophenolate: should we measure free, total, trough, AUC., glucuronide or what?
PathCentre Perth. Perth, Australia, 29.09.2004.
332. Use of LC/MS-MS in immunosuppressive drug monitoring. Experience with C₂ level monitoring in adult and pediatric patients.
PathCentre Perth. Perth, Australia, 29.09.2004.
333. Monitoring thiopurine methyltransferase – phenotype or genotype.
PathCentre Perth. Perth, Australia, 30.09.2004.
334. Impact of pharmacogenetics on therapeutic drug monitoring.
PathCentre Perth. Perth, Australia, 30.09.2004.
335. Current trends in immunosuppressive drug monitoring.
Experts' Meeting. Sydney, Australia, 05.10.2004.
336. Free and total MPA – relationship to efficacy (rejection rates) and safety. CellCept Therapeutic Drug Monitoring Advisory Board Meeting. New York, USA, 10.12.2004.
337. Drug Monitoring von Immunsuppressiva bei Nierentransplantation.
Fortbildungsveranstaltung UKG, 50 Jahre Nierentransplantation – heutiger Stand. Göttingen, Germany, 17.02.2005.
338. Use of LC-MS/MS in immunosuppressive drug monitoring.
Waters forum: "Applications of mass spectrometry and separation strategies in clinical chemistry". Milford, USA, 31.03.2005.
339. Bio-markers: the link between therapeutic drug monitoring and pharmacodynamics.
Symposium: Advances in Transplantation Therapeutics Conference. 9th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology. Louisville, USA, 23.04.2005.
340. Evidence base for use of HPLC/MS generated target ranges – the needs -.
9th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology. Louisville, USA, 24.04.2005.
341. The role of therapeutic drug monitoring in immunosuppressant therapy. Symposium: Drug investigation (S20) organized with IATDMCT. 16th IFCC-FESCC European Congress of Clinical Chemistry and Laboratory Medicine. Glasgow, UK, 11.05.2005.
342. Use of LC-MS/MS in immunosuppressive drug monitoring.
Satellite symposium : Tandem mass spectrometry. XIII. World Congress of Pathology and Laboratory Medicine. Istanbul, Turkey, 28.05.2005.

343. Use of LC-MS/MS in immunosuppressive drug monitoring.
AACC-Workshop, XIX International Congress of Clinical Chemistry IFCC/AACC
2005 Annual Meeting, Orlando, USA, 24.07.2005.
344. Reliable measurement of immunosuppressants simultaneously using HPLC/tandem
mass spectrometry.
Industry workshop (Applied Biosystems): Results of recent clinical research-
applications of HPLC/tandem mass spectrometry in the clinical laboratory. XIX
International Congress of Clinical Chemistry IFCC/AACC 2005 Annual Meeting,
Orlando, USA, 26.07.2005.
345. Pharmakokinetik und Drug Monitoring von CellCept.
Kongress für Nephrologie 2005. Mittagssymposium: „Mycophenolatmofetil in der
Nephrologie – neue Möglichkeiten“. Saarbrücken, Germany, 18.09.2005.
346. Spettrometria di Massa e TDM. Lab Automation and Medical Decision Making, La
spettrometria nell'automazione del TDM e della tossicologia di laboratorio.
Villa Tacchi, Villalta di Gazzo Padovano, Italy, 07.10.2005
347. Pharmakokinetik und Drug Monitoring von MMF – erhöhte Sicherheiten und
Effizienz?
36. Transplantationsforum des Transplantationszentrums der Universität München
Großhadern. Interaktiver Workshop „Safety First“. München, Germany, 22.10.2005.
348. Immunosuppressive drug monitoring using HPLC/tandem mass spectrometry. The
Trinity College Master of Science Course in Clinical Chemistry. Dublin, 03.02.2006.
349. Impact of pharmacogenetics on therapeutic drug monitoring.
The Trinity College Master of Science Course in Clinical Chemistry. Dublin, Ireland,
03.02.2006.
350. Pathology education and research in Germany.
Faculty of Pathology, The Royal College of Physicians of Ireland, Annual
Symposium: The evolution of pathology practice – the past, the present and the
future. Dublin, Ireland, 03.02.2006.
351. FDCC: free MPA, AcMPAG substudy interim report.
FDCC Steering Committee Meeting. Brussels, Belgium, 22.02.2006.
352. Impact of pharmacogenetics on therapeutic drug monitoring.
24th Euregio Conference of Clinical Chemistry and Laboratory Medicine. Liège,
Belgium, 24.03.2006.
353. The role of therapeutic drug monitoring in immunosuppressant therapy.
VI Jornada de Monitorización de Fármacos y Toxicología Clínica. Madrid, Spain,
21.04.2006.
354. Mass spectrometry in immunosuppressive drug monitoring.
Analytica Conference 2006, Symposium: Frontiers in Therapeutic Drug Monitoring /
Joint Meeting of the DGKL and the IATDMCT. München, Germany, 25.04.2006

355. Anwendungsfelder der Massenspektrometrie in der Klinischen Chemie.
19. Norddeutsches Gespräch in Klinischer Chemie. Nörten-Hardenberg, Germany, 13.05.2006.
356. Drug Monitoring von Immunsuppressiva.
Transplantationskonferenz Nephrologisches Zentrum Niedersachsen. Hannoversch Münden, Germany, 11.07.2006.
357. FDCC – Free MPA, AcMPAG substudy report.
FDCC Steering Committee. Boston, USA, 25.07.2006.
358. Is free MPA useful to predict the risk for leukopenia and infection? IATDMCT
Symposium: Therapeutic Drug Monitoring of MPA: Why and How? AACC 2006
Annual Meeting and Clinical Lab Exposition. Chicago, USA, 26.07.2006.
359. Drug Monitoring von CellCept®: Neueste Studienergebnisse.
Kongress für Nephrologie, Symposium: Verbesserung des Outcomes nach
Nierentransplantation. Essen, Germany, 25.09.2006.
360. Impact of pharmacogenetics on therapeutic drug monitoring.
14th Meeting of the Balkan Clinical Laboratory Federation. Sofia, Bulgaria,
28.09.2006.
361. OptiScore.
OptiScore Steering Committee Meeting. Amsterdam, The Netherlands, 25.10.2006.
362. Clinical applications of mycophenolic acid monitoring.
Therapeutic drug monitoring & pharmacogenetics symposium. Buenos Aires,
Argentina, 15.11.2006.
363. Drug Monitoring bei Immunsuppression.
3. Workshop Kinderlebertransplantation, Wirkungsmechanismen der
Immunsuppressiva. Hamburg, Germany, 17.02.2007.
364. Immunosuppressive Drug Monitoring.
VII. Ulusal Klinik Biyokimya Kongresi. Antalya, Turkey, 21.04.2007.
365. Immunsuppressiva – Monitoring.
Fortbildungsveranstaltung Nierentransplantation. UMG, Göttingen, Germany,
26.04.2007.
366. Bio-markers: the link between therapeutic drug monitoring and pharmacodynamics.
Session: Drugs of abuse, therapeutic drug monitoring. 17th IFCC – FESCC European
Congress of Clinical Chemistry and Laboratory Medicine. Amsterdam, The
Netherlands, 06.06.2007.
367. Drug Monitoring von CellCept®.
Wissenschaftliches Symposium: “Innovation für die Klinik - Das Labor mit Roche
Diagnostiks”. Mannheim, Germany, 23.06.2007.

368. Drug Monitoring von CellCept®.
3. Tutzing Symposium: Interdisziplinäres Treffen Nieren- und Lebertransplantation. Evangelische Akademie Tutzing, Germany, 02.07.2007.
369. Pathology Education and Research in Germany.
Lunch Symposium 1: Bricks, Tools, Chips, Brains for the Modernisation of Laboratory Medicine in Italy and Europe. 24th World Congress of Pathology and Laboratory Medicine. Kuala Lumpur, Malaysia, 23.08.2007.
370. Immunosuppressive Drug Monitoring.
Symposium: Therapeutic Drug Monitoring, 24th World Congress of Pathology and Laboratory Medicine. Kuala Lumpur, Malaysia, 23.08.2007.
371. New developments in the field of mycophenolic acid (MPA-Monitoring).
Immunosuppressive Drug Monitoring: Global Trends and Local Perspectives. Institute for Medical Research (IMR). Kuala Lumpur, Malaysia, 24.08.2007.
372. Evaluation of the Roche MPA IMPDH inhibition assay.
Workshop Roche: Mycophenolate monitoring: What, Why and How. 10th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology. Nice, France, 11.09.2007.
373. Applications of mass spectrometry in clinical chemistry.
6th National Congress on Laboratory Medicine. Sibiu, Romania, 11.10.2007.
374. Future challenges for pathology and laboratory medicine – the role of WASPaLM.
Tavola Rotonda: La Medicina di Laboratorio ed il miglioramento delle cure: un servizio essenziale, una prospettiva interdisciplinare, una visione olistica. 21° Congresso Nazionale, Società Italiana di Medicina di Laboratorio. Riva del Garda, Italy, 25.10.2007.
375. Applications of mass spectrometry in proteomics and the clinical laboratory. Institute of Genomics and Integrative Biology (IGIB). Delhi, India, 10.12.2007.
376. Applications of mass spectrometry in proteomics and the clinical laboratory. Faculty of Pathology, The Royal College of Physicians of Ireland. Mini Seminar "Proteomics in Laboratory Medicine". Dublin, Ireland, 07.02.2008.
377. New developments in the field of mycophenolic acid (MPA-Monitoring).
The Trinity College Master of Science Course in Clinical Chemistry. Dublin, Ireland, 08.02.2008.
378. Bio-markers: the link between therapeutic drug monitoring and pharmacodynamics.
The Trinity College Master of Science Course in Clinical Chemistry. Dublin, Ireland, 08.02.2008.

379. Bio-markers: the link between therapeutic drug monitoring and pharmacodynamics. American Society for Clinical Pharmacology and Therapeutics (ASCPT) 109th Annual Meeting. Symposium: Transitioning immunosuppressive drug management through the application of novel biomarkers: what's here, what's near? Orlando, USA, 04.04.08.
380. Drug Monitoring von Mycophenolat Mofetil bei nierentransplantierten Patienten. 19. Münsteraner Symposium: Management schwieriger Fälle nach Nierentransplantation. Münster, Germany, 17.05.2008.
381. Biomarkers: the link between drug monitoring and pharmacodynamics. National Meeting of the Bulgarian Society of Clinical Laboratory. Varna, Bulgaria, 06.06.08.
382. Biomarker: Ein Bindeglied zwischen Drug Monitoring und Pharmakodynamik. 5. Jahrestagung Deutsche Vereinte Gesellschaft für Klinische Chemie und Laboratoriumsmedizin (DGKL). 22. Sitzung: Drug Monitoring – Anwendungsfelder im Wandel. Mannheim, Germany, 24.09.2008.
383. Biomarkers as an adjunct to immunosuppressive drug monitoring. International Conference Therapeutic Drug Monitoring in Optimizing the Immunosuppressive Therapy. Session 3: PK/PD modelling and novel biomarkers in the field of transplantation. Warsaw, Poland, 26.09.2008.
384. New developments in the field of mycophenolic acid monitoring. Fundación Investigar. 2nd Buenos Aires Therapeutic Drug Monitoring and Pharmacogenetics Symposium. Buenos Aires, Argentina, 23.10.2008.
385. Bio-markers: as a link between therapeutic drug monitoring and pharmacodynamics. Fundación Investigar. 2nd Buenos Aires Therapeutic Drug Monitoring and Pharmacogenetics Symposium. Buenos Aires, Argentina, 23.10.2008.
386. Drug Monitoring von CellCept – neue Möglichkeiten und Grenzen. MPA-Spiegel Bestimmung – Neue Chancen im Immunmonitoring? Transplantationschirurgischer Workshop. Klinik für Allgemein- Viszeral- und Transplantationschirurgie. MHH. Hannover, Germany, 11.11.2008.
387. Drug Monitoring von CellCept. 17. Jahrestagung der Deutschen Transplantationsgesellschaft. Plenarsitzung. Neues aus der forschenden Pharmaindustrie. Bochum, Germany, 21.11.2008.
388. New developments in immunosuppressive drug monitoring. Joint Symposium, Korea University. Seoul, South Korea, 01.12.2008.
389. Recent advances in therapy and therapeutic drug monitoring of immunosuppressant drugs. XXXVth Annual National Conference of Association of Clinical Biochemists of India. Therapeutic Drug Monitoring Symposium. Kolkata, India, 20.12.2008.

390. Bio-markers – the link between immunosuppressive drug monitoring and pharmacodynamics.
30 Years of Liver Transplantation in Eurotransplant. Universitätsklinikum Schleswig-Holstein. Kiel, Germany, 13.02.2009.
391. Impact of Pharmacogenetics on therapeutic drug monitoring.
Symposium: Advances in Therapeutic Drug Monitoring. XXV World Congress of Pathology and Laboratory Medicine, Pathology Update 2009. Sydney, Australia, 14.03.2009.
392. Future of Pathology.
Eva Raik Presidential Symposium. XXV World Congress of Pathology and Laboratory Medicine, Pathology Update 2009. Sydney, Australia, 14.03.2009.
393. Pharmakokinetik und Pharmakodynamik der Mycophenolsäure, sowie Spiegelmessungen (AUC) bei CellCept.
Transplantationskonferenz. Netzwerk Neue Niere e.V., Hamburg, Germany, 21.04.2009.
394. Bio-markers as a link between therapeutic drug monitoring and pharmacodynamics.
IX. National Congress of the Turkish Society of Clinical Biochemistry. Antalya, Turkey, 25.04.2009.
395. Impact of pharmacogenetics on therapeutic drug monitoring.
59th Congresso Nazionale, Il patologo clinico nella personalizzazione di una realtà globalizzata. Tivoli, Italy, 13.05.2009.
396. Individualisierte Immunsuppression – Berücksichtigung der Pharmakokinetik und Pharmakodynamik.
Charité-NTx-Symposium: One size fits all? – Sind individuelle Strategien nötig? Berlin, Germany, 14.06.2009.
397. Biomarker zur Optimierung der Therapie mit Immunsuppressiva. Expertentreffen “Pharmakodynamische Marker als Instrument zur Optimierung der Immunsuppression in der Transplantationsmedizin”. Stuttgart, Germany, 10.07.2009.
398. Future of Pathology.
TongJi University. Shanghai, China. 03.09.2009.
399. Future of Pathology.
Zhejiang Medical University. Hangzhou, China. 04.09.2009.
400. Future of Pathology.
Nanjing Medical University. Nanjing, China. 08.09.2009.

401. Biomarkers as a link between therapeutic drug monitoring and pharmacodynamics. Southeast University Medical School. Nanjing, China. 09.09.2009.
402. Biomarkers as a link between therapeutic drug monitoring and pharmacodynamics. Nanjing University School of Medicine. Nanjing, China. 10.09.2009.
403. New developments in immunosuppressive drug monitoring. National Meeting of the Bulgarian Society of Clinical Laboratory (BSCL). Burgas, Bulgaria. 25.09.2009.
404. Drug Monitoring. Kongress für Nephrologie 2009. 1. Jahrestagung der Deutschen Gesellschaft für Nephrologie. Göttingen, Germany, 28.09.2009
405. The role of CD4+ ATP measurement to achieve personalized immunosuppression in adult and pediatric transplant population. Pre-congress symposium – personalized immunosuppressive therapy. 11th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology. Montreal, Canada, 03.10.2009.
406. Discussion of biomarkers for monitoring immunosuppressive therapy. Abbott Transplant Roundtable. Montreal, Canada, 06.10.2009
407. Impact of pharmacogenetics on therapeutic drug monitoring. Plenary lecture. III Congresso Nacional del Laboratorio Clinico. Valencia, Spain, 15.10.2009.
408. Impact of pharmacogenetics on therapeutic drug monitoring. Keynote lecture. 36th Annual National Conference of the Association of Clinical Biochemists of India. Kochin, India, 06.11.2009.
409. Biomarker: ein Bindeglied zwischen Drug Monitoring und Pharmakodynamik. Gemeinsamer Weg von Laboratoriums- und Transfusionsmedizin. 25 Jahre Jubiläumssymposium. Bad Oeynhausen, Germany, 28.11.2009.
410. Future of Pathology and Laboratory Medicine. Seminar, Department of Chemical Pathology, The Chinese University of Hong Kong, Faculty of Medicine. Hong Kong, 07.04.2010.
411. New developments in immunosuppressive drug monitoring. Dinner Lecture. Hong Kong Society of Clinical Chemistry. Hong Kong, 09.04.2010.
412. Biomarkers as a link between TDM and pharmacodynamics. Il ruolo del laboratorio nel monitoraggio terapeutico dei farmaci (TDM). 60. Congresso Nazionale. AIPaCMem. Montesilvano, Italy, 21.05.2010.

413. Future of Pathology and Laboratory Medicine.
VIth National Meeting of BSCL. Borovetz, Bulgaria, 03.09.2010.
414. Future of Pathology and Laboratory Medicine.
New insights into Biochemistry III. 17th Congress of the Romanian Society of Laboratory Medicine (SRML). Targu Jiu, Romania, 09.09.2010.
415. Biomarkers as a link between TDM of immunosuppressants and pharmacodynamics.
New insights into Biochemistry III. 17th Congress of the Romanian Society of Laboratory Medicine (SRML). Targu Jiu, Romania, 09.09.2010.
416. Applications of mass spectrometry and biomarkers in therapeutic drug monitoring.
1st AB SCIEX European Conference on MS/MS (ECMSMS) 2010. Amsterdam, The Netherlands, 07.10.2010.
417. Future of Pathology.
11th International Congress – ASCPALM, 7th National Congress IACP, Jakarta, Indonesia, 20.10.2010.
418. Impact of pharmacogenetics on therapeutic drug monitoring.
Inauguration lecture. 11th International Congress – ASCPALM, 7th National Congress IACP. Jakarta, Indonesia, 21.10.2010.
419. Biomarkers as a link between TDM of immunosuppressants and pharmacodynamics.
Symposium 2: Therapeutic Drug Monitoring / Drug of Abuse. 11th International Congress – ASCPALM, 7th National Congress IACP, Jakarta, Indonesia, 21.10.2010.
420. Use of endogenous biomarkers to achieve personalized immunosuppression in transplant recipients.
Seminar, Abbott Park, IL, USA, 29.10.2010.
421. Future of Clinical Biochemistry, Laboratory Medicine and Pathology. Inauguration lecture. ACBICON 2010 – 37th National Conference of ACBI. Mumbai, India, 14.12.2010.
422. ATP CD4+ concentrations monitoring as a biomarker predictive of over-immunosuppression in transplant patients.
Symposium: Biomarkers of immunosuppression, immunoreactivity and graft injury (II), III Siemens European Symposium on Clinical and Translational Immunosuppression. Barcelona, Spain, 10.02.2011.
423. Drug monitoring of immunosuppressants.
European Academy of Transplantation. Hannover, Germany, 16.04.2011.
424. Impact of pharmacogenetics on therapeutic drug monitoring.
Türk Klinik Biyokimya Dernegi. XI. Ulusal Klinik Biyokimya Kongresi. Antalya, Turkey, 29.04.2011.

425. Future of pathology and laboratory medicine.
Türk Klinik Biyokimya Dernegi. XI. Ulusal Klinik Biyokimya Kongresi. Antalya, Turkey, 29.04.2011.
426. Future of pathology and laboratory medicine.
Unilabs Leader's Conference. Nizza, France, 09.05.2011.
427. Future of pathology and laboratory medicine.
61. Congresso Nazionale AIPaCMeM. Caserta, Italy, 11.05.2011.
428. Endogenous biomarkers and pharmacogenetic markers.
Roundtable Abbott. Berlin, Germany, 17.05.2011.
429. Use of endogenous biomarkers to achieve personalized immunosuppression in transplant recipients.
IFCC – WorldLab – EuromedLab Berlin 2011, Berlin, Germany, 19.05.2011.
430. Future of Pathology.
Plenary Session. Chinese National Congress. Beijing, China, 26.05.2011.
431. Aktuelle Entwicklungen auf dem Gebiet des Drug Monitoring von Immunsuppressiva.
Nierentransplantationssymposium. Berlin, Germany, 04.06.2011.
432. Pharmakokinetik und Pharmakodynamik von Immunsuppressiva.
Fortbildungsveranstaltung TX-Akademie. Hamburg, Germany, 21.06.2011.
433. The clinical value of mycophenolic acid monitoring.
Webinar. AACC Annual Meeting. Atlanta, USA, 27.07.2011.
434. Pharmacogenetics and individualized drug therapy.
Plenary Session. VII National Conference of Clinical Laboratory. Varna, Bulgaria, 09.09.2011.
435. Impact of pharmacogenetics on therapeutic drug monitoring.
Plenary Session. 19th Meeting of Balkan Clinical Laboratory Federation (BJCL). Bucharest, Romania, 22.09.2011.
436. Therapeutic drug monitoring – key to personalized medicine.
Opening Lecture. Stuttgart, Germany, 02.10.2011.
437. Therapeutisches Drug Monitoring: State of the Art und Optionen für Biomarker.
Satelliten-Symposium. DTG-Tagung. Regensburg, Germany, 07.10.2011.

438. Use of endogenous biomarkers to achieve personalized immunosuppression in transplant recipients.
WASPaLM and The International Association of Therapeutic Drug Monitoring and Clinical Toxicology: Pharmacodynamic Monitoring of Targeted Drug Therapy. XXVIth World Congress WASPaLM. Las Vegas, USA, 20.10.2011.
439. Pharmacokinetics and pharmacodynamics of immunosuppressive drugs. Pathology and Laboratory Medicine Grand Rounds Seminar. Perelman School of Medicine, University of Pennsylvania. Philadelphia, USA, 24.10.2011.
440. Leber und Medikamente – nach der Lebertransplantation: Immunmonitoring, Biomarker, Immuntoleranz. Symposium: Im Mittelpunkt steht die Leber. Universitätsklinikum Schleswig-Holstein. Kiel, Germany, 12.11.2011.
441. Drug monitoring of immunosuppressants.
The Trinity College Master of Science Course in Clinical Chemistry. Dublin, Ireland, 18.11.2011.
442. Use of endogenous biomarkers to achieve personalized immunosuppression in transplant recipients.
38th Annual Conference of ACBI 2011. Gwalior, India, 04.12.2011.
443. Therapeutic drug monitoring key to personalized pharmacotherapy.
Keynote address. 38th Annual Conference of ACBI 2011. Gwalior, India, 05.12.2011.
444. Biomarkers in Transplantation.
Workshop: Cooperation Kompetenzzentrum für Organtransplantation Südniedersachsen and Dept. Nephrology and Transplantation, Medical Faculty of the University St. Petersburg, Russland. Göttingen, Germany, 09.12.2011.
445. Pharmacogenetics and individualized drug therapy.
Plenary Lecture. 7th National Youth Congress of Laboratory Medicine. Chinese Society of Laboratory Medicine. Nanjing, China, 04.05.2012.
446. Pharmacogenetics and individualized drug therapy.
Symposium: New technology and new development of laboratory medicine. Chinese Society of Laboratory Medicine Beijing branch. Beijing, China, 07.05.2012.
447. The future of pathology and laboratory medicine.
Opening Lecture. Baltic Congress of Laboratory Medicine. Vilnius, Lithuania, 10.05.2012.

448. Use of endogenous biomarkers to achieve personalised immunosuppression. Symposium: Therapeutic drug monitoring. XXXIII Nordic Congress in Clinical Chemistry. Reykjavik, Finland, 14.06.2012.
449. Pharmacokinetic monitoring and biomarkers as a means to improve outcome in transplantation. Symposium: Immunosuppressive therapeutic drug monitoring – where are we headed? AACCC Annual Meeting 2012. Los Angeles, USA, 16.07.2012.
450. Biomarkers to achieve personalized immunosuppression in transplantation. Plenary Lecture. Transplantation Symposium. Near East University Faculty of Medicine. Lefkosa, Cyprus, 24.09.2012.
451. Therapeutic drug monitoring – state of the art and options for biomarkers. IX National Congress of Clinical Laboratory. Borovetz, Bulgaria, 28.09.2012.
452. TDM und Pharmakokinetik von Everolimus bei pädiatrischen nierentransplantierten Patienten. Prüfertreffen der internationalen pädiatrischen Everolimus-Studie CRADA 2314. Frankfurt/Main, Germany, 10.10.2012.
453. The future of pathology and laboratory medicine. Symposium Women's Health. XLII Congreso Mexicano de Patología Clínica, XXI Congreso Latinoamericano de Patología Clínica. Cancún, Mexico, 26.10.2012.
454. Pharmacogenetics and individualized drug therapy. Session II: Laboratory Methods Standardization/TDM Biomarkers. International Pathology Symposium 2012. Riyadh, Saudi Arabia, 24.11.2012.
455. Immunosuppressive drug monitoring: State of the art and options for biomarkers. Session II: Laboratory Methods Standardization/TDM Biomarkers. International Pathology Symposium 2012. Riyadh, Saudi Arabia, 24.11.2012.
456. Use of endogenous biomarkers to achieve personalized immunosuppression. Session VIII: Biomarkers and Tolerance Induction in Transplantation. The Saudi International Congress on New Frontiers in Organ Transplantation (SICOT) 2013. Riyadh, Saudi Arabia, 05.03.2013.
457. Therapeutic drug monitoring – key to personalized pharmacotherapy. Plenary lecture. The 30th Annual Meeting for the Japanese Society of Therapeutic Drug Monitoring. Kumamoto, Japan, 25.05.2013.
458. Monitoring donor/recipient cfDNA ratio in transplantation – A new approach to improve chances of long-term graft survival. Roundtable. Board meeting Chronix Biomedical. Chicago, USA, 06.06.2013.

459. Monitoring donor/recipient cfDNA ratio in transplantation – A new approach to improve chances of long-term graft survival.
Roundtable. Chronix Biomedical. Houston, USA, 31.07.2013.
460. TDM of immunosuppressive drugs – state of the art and options for biomarkers.
WASPaLM – WPF session: New perspectives for the early diagnosis and laboratory monitoring. 63rd National Congress of AIPaCMeM. Perugia, Italy, 17.09.2013.
461. Biomarkers to achieve personalized immunosuppression in transplantation.
Workshop: TDM of immunosuppressants and options for biomarkers. 13th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology. Salt Lake City, USA, 23.09.2013.
462. External quality assurance in medical laboratory & costing in universal health coverage.
Round Table Discussion. 13th Asia-Pacific Federation for Clinical Biochemistry and Laboratory Medicine Congress. IACP-WASPaLM Bali, Indonesia, 27.10.2013.
463. Pharmacokinetic monitoring and biomarkers as a means to improve outcome in transplantation.
Symposium Pharmacogenomic. 13th Asia-Pacific Federation for Clinical Biochemistry and Laboratory Medicine Congress. Bali, Indonesia, 28.10.2013.
464. Future Laboratory Medicine: LC-MS vs Immunoassays.
Plenary Lecture 4: WASPaLM. 13th Asia-Pacific Federation for Clinical Biochemistry and Laboratory Medicine Congress. Bali, Indonesia, 30.10.2013.
465. Circulating DNA, signatures of tolerance and intracellular ATP.
Autumn Transplantation Meeting (Joint transplant meeting of the Bulgarian Academy of Science and Art (BASA), Bulgarian Society of Transplantation, Bulgarian Transplantation Agency). Sofia, Bulgaria, 18.11.2013.
466. Pharmacokinetic monitoring and biomarkers as a means to improve outcome in transplantation.
Lecture I. The Trinity College 2013 Master of Science Course in Clinical Chemistry. Dublin, Ireland, 22.11.2013.
467. Future Laboratory Medicine: Pharmacogenetics and individualized drug therapy.
Lecture II. The Trinity College 2013 Master of Science Course in Clinical Chemistry. Dublin, Ireland, 22.11.2013.
468. Future Laboratory Medicine: LC-MS vs. Immunoassays.
IFCC TF-YS educational course: Promising Pathways for Young Scientists – Today & Tomorrow. ACBI (Association of Clinical Biochemists of India) Annual Conference 2013. Delhi, India, 05.12.2013.

469. Pharmacokinetic monitoring and biomarkers as a means to improve outcome in transplantation.
Symposium. ACBI (Association of Clinical Biochemists of India) Annual Conference 2013. Delhi, India, 05.12.2013.
470. LC/MS vs. Immunoassays.
Plenary Session. Cascadion Summit. Thermo Fisher Scientific Oy. Vantaa, Finland, 05.02.2014.
471. Biomarkers in transplantation.
Bio-Rad Digital Biology Center event „Graft integrity using Droplet Digital™ PCR”. Bio-Rad Laboratories, Munich. Hardenberg BurgHotel, Nörten-Hardenberg, Germany, 29.03.2014.
472. Future Laboratory Medicine: LC-MS vs Immunoassays.
IFCC-Abbott Visiting Lectureship. Symposium: The future of laboratory medicine. IATDMCT Regional Meeting 2014. Sibiu, Romania, 06.06.2014.
473. Pharmacokinetic monitoring and biomarkers as a means to improve outcome in transplantation.
IFCC-Abbott Visiting Lectureship. Symposium: Laboratory Medicine in a new era. IATDMCT Regional Meeting 2014. Sibiu, Romania, 07.06.2014.
474. Biomarkers to achieve personalized immunosuppression in transplantation.
WASPaLM Symposium: Biomarkers and personalized pharmacotherapy. 22nd International Congress of Clinical Chemistry and Laboratory Medicine (IFCC WorldLab Istanbul 2014). Istanbul, Turkey, 23.06.2014.
475. Biomarkers in transplantation / Use of endogenous biomarkers to achieve personalized immunosuppression.
Plenary lecture. 2014 International Congress of Pathology & Laboratory Medicine (ICPaLM) and 48th Malaysia-Singapore Congress of Medicine. Kuala Lumpur, Malaysia, 26.08.2014.
476. Biomarkers in transplantation – graft-derived circulating cfDNA and signatures of tolerance.
Joint Session SIPMeT/AIPaCMeM: New technologies for research and diagnosis. 2nd Joint Meeting of Pathology and Laboratory Diagnostics (64th National Congress AIPaCMeM and 32nd National Congress of SIPMeT): “Molecular mechanisms of disease: from basic research to clinical practice”. Palermo, Italy, 17.09.2014.
477. Personalized Medicine.
The Goettingen Spirit Summer School „Biological Research in Dentistry“. Universitätsmedizin Göttingen. Göttingen, Germany, 02.10.2014.
478. Ist therapeutisches Drug Monitoring noch relevant?
Session: Update Klinische Pharmakologie. 51. Kongress der Südwestdeutschen Gesellschaft für Innere Medizin. Stuttgart, Germany, 18.10.2014.

479. Diagnostic tools for aspergillosis.
Seminar, DiaSys Diagnostic China. Shanghai, China, 23.10.2014.
480. Use of endogenous biomarkers to achieve personalized immunosuppression.
Seminar, DiaSys Diagnostic China. Shanghai, China, 23.10.2014.
481. Use of endogenous biomarkers to achieve personalized immunosuppression.
Bei Shizhang Lecture, Institute of Biophysics, Chinese Academy of Sciences.
Beijing, China, 24.10.2014.
482. Diagnostic tools for aspergillosis and circulating cell-free DNA.
Seminar. Department of Dermatology, Peking University First Hospital. Beijing,
China, 26.10.2014.
483. Pharmakokinetik und Pharmakodynamik von Fingolimod.
Nationaler Workshop: „S1P Rezeptormodulation – Erkenntnisse über ein innovatives
Wirkprinzip“. Medical Advisory Board Meeting. Novartis Pharma GmbH. Frankfurt,
29.10.2014.
484. Pharmakokinetisches Monitoring und Biomarker zur Erzielung einer personalisierten
Immunsuppression in der Transplantationsmedizin.
Fachtagung: „DIAGNOSE + LABOR, Review 2014“. DELAB GmbH & Co. KG.
Mainz, Germany, 08.11.2014.
485. Biomarkers to achieve personalized immunosuppression in transplantation.
6th Synevo Clinical Research Symposium. Bucharest, Romania, 21.11.2014.
486. Graft-derived cfDNA as a marker of transplant injury.
Consensus Conference on biomarker-based therapeutic drug monitoring in solid
organ transplantation. Barcelona, Spain, 10.12.2014.
487. Graft-derived cfDNA as biomarker of graft integrity in transplant recipients: a
review.
Session “Biomarkers predictive of graft clinical outcome”. IV Symposium on
Biomarkers of Immunosuppression and Clinical Outcome in Transplantation: New
Approaches on TDM of Immunosuppressive Drugs. Barcelona, Spain, 12.12.2014.
488. Biomarkers to achieve personalized immunosuppression in transplantation.
Seminar. Università degli Studi di Milano. Milan, Italy, 09.02.2015.
489. Minimal requirements for therapeutic drug monitoring.
Plenary Symposium: Pediatric transplantation in developing countries. IPTA 8th
Congress on Pediatric Transplantation. San Francisco, USA, 30.03.2015.
490. Circulating cell-free DNA as a diagnostic tool in transplantation and cancer.
Seminar. The Digital Biology Center, Bio-Rad. Pleasanton, USA, 31.03.2015.
491. LC/MS vs. immunoassays for therapeutic drug monitoring.
The XV. National Clinical Biochemistry Congress. Fethiye, Turkey, 25.04.2015.

492. Perspectives on personalized molecular diagnostics. Plenary session. 70 years Medical University of Plovdiv Anniversary Scientific Conference “Science for Health”. Plovdiv, Bulgaria, 21.05.2015.
493. Biomarkers as a means to improve outcome in transplantation. Symposium: Biomarkers – key to personalized medicine. 21st IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicine. Paris, France, 25.06.2015.
494. Use of endogenous biomarkers to achieve personalized immunosuppression. International Society for Enzymology Annual Conference 2015. Corfu, Greece, 30.06.2015.
495. Personalized medicine. The Göttingen Spirit Summer School: “Biological Research in Dentistry”. Göttingen, Germany, 20.08.2015.
496. Biomarkers in cancer and transplantation. Opening lecture. VIII National Conference of Clinical Laboratory. Borovetz, Bulgaria, 10.09.2015.
497. Biomarkers for personalized immunosuppression. 3rd ESPT Conference “Integration of Pharmacogenomics in Clinical Decision Support”. Budapest, Hungary, 08.10.2015.
498. cfDNA and immunosuppression. Symposium “Biomarker, Immunosuppressive and Toxicology”. 14th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology. Rotterdam, The Netherlands, 12.10.2015.
499. Research on molecular biomarkers in cancer and transplantation including a framework for personalized medicine. Lecture. The Trinity College 2015 Master of Science Course in Clinical Chemistry. Dublin, Ireland, 30.10.2015.
500. Pharmakogenomik – Biomarker in der Onkologie und zielgerichtete Therapie. Fachtagung: „DIAGNOSE + LABOR, Review für Labor und Klinik/2. Teil“. DELAB GmbH & Co. KG. Mainz, Germany, 07.11.2015.
501. Future of laboratory medicine – challenges and opportunities. Session “Young specialists in lab medicine of the future – preparing together”. XXVIII WASPaLM World Congress. Cancún, Mexico, 18.11.2015.
502. Biomarkers in transplantation – graft derived circulating cfDNA and signatures of tolerance. Session “Advances in therapeutic drug monitoring to achieve personalized pharmacotherapy”. XXVIII WASPaLM World Congress. Cancún, Mexico, 20.11.2015.

503. Laboratoriumsmedizin: Herausforderung und Chancen.
Festvortrag. "Moderne Laboratoriumsmedizin im HDZ NRW": Eröffnung des neuen 24-Stunden-Labor mit Laborautomation des Instituts für Laboratoriums- und Transfusionsmedizin. Bad Oeynhausen, Germany, 22.04.2016.
504. „Labs Are Vital™“ - Herausforderungen und Chancen der Laboratoriumsmedizin.
DELAB-Fachtagung. DELAB GmbH & Co. KG. Mainz, Germany, 17.06.2016.
505. Circulating cell-free DNA as a diagnostic tool in cancer.
International Society for Enzymology Annual Meeting 2016 (ISE 2016):
International Laboratory Medicine and Pathobiology Conference. Syros, Greece,
02.07.2016.
506. Graft-derived cell-free DNA as a biomarker in organ transplantation.
Session "Precision medicine delivered by advances in circulating cell-free DNA
diagnostics". 68th AACC Annual Scientific Meeting & Clinical Lab Expo.
Philadelphia, USA, 03.08.2016.
507. Circulating cell-free DNA as a diagnostic tool in transplantation and cancer.
Keenan Research Seminar Series. Li Ka Shing Knowledge Institute, St. Michael's
Hospital, Toronto, Canada, 05.08.2016.
508. Circulating cell-free DNA as a diagnostic tool in transplantation and cancer.
Invited lecture. The 32nd World Congress of Biomedical Laboratory Science (IFBLS
2016). Kobe, Japan, 02.09.2016.
509. Circulating tumor DNA – a promising diagnostic tool in cancer.
WASPaLM Symposium "Molecular diagnostics in cancer management". 4th Joint
EFLM-UEMS Congress "Laboratory medicine at the clinical interface". Warsaw,
Poland, 22.09.2016.
510. Laboratory medicine – challenges and opportunities.
Plenary session. IX National Conference of Clinical Laboratory with international
participation. Varna (Golden Sands), Bulgaria, 30.09.2016.
511. Circulating tumor DNA – a promising diagnostic tool in cancer.
The Göttingen Spirit Summer School: "Biological Research in Dentistry". Göttingen,
Germany, 05.10.2016.
512. Molekulare Diagnostik für die personalisierte Immunsuppression in der
Transplantation.
Fachtagung: „DIAGNOSE + LABOR, Review für Labor und Klinik/3. Teil“.
DELAB GmbH & Co. KG. Mainz, Germany, 11.11.2016.
513. Laboratory medicine – challenges and opportunities.
Laboratory Section. 8th Edition of Synevo Clinical Research Symposium. Bucharest,
Romania, 25.11.2016.

514. Graft-derived cell-free DNA as a diagnostic tool in transplantation.
Session “Biology and Immunology”. 3rd International Meeting on Cell-Free DNA.
Copenhagen, Denmark, 06.04.2017.
515. Laboratory medicine – challenges and opportunities.
XVIIth Congress of Clinical Biochemistry with international participation. Turkish
Society of Clinical Biochemistry. Kyrenia, North Cyprus, 06.05.2017.
516. Graft-derived cell-free DNA as a liquid biopsy in transplantation.
International Society for Enzymology Annual Conference: Advances in Laboratory
Medicine and Pathobiology 2017 (ISE 2017). Santorini, Greece, 19.06.2017.
517. Cell-free DNA for disease stratification and prognosis in head and neck cancer.
International Society for Enzymology Annual Conference: Advances in Laboratory
Medicine and Pathobiology 2017 (ISE 2017). Santorini, Greece, 19.06.2017.
518. Circulating cell-free DNA as a diagnostic tool in cancer.
Opening lecture. X National Congress of Clinical Laboratory with international
participation. Borovetz, Bulgaria, 07.09.2017.
519. Circulating cell-free DNA as a new tool for personalized pharmacotherapy.
Plenary lecture. 15th Congress of the International Association of Therapeutic Drug
Monitoring & Clinical Toxicology. Kyoto, Japan, 27.09.2017.
520. Molekulare Diagnostik der Transplantatrejektion.
10. Düsseldorfer Nieren- und Hochdrucktage. Heinrich-Heine-Universität
Düsseldorf, Germany, 06.10.2017.
521. Circulating tumor DNA – a promising diagnostic tool in cancer.
The Göttingen Spirit Summer School: “Biological Research in Dentistry”. Göttingen,
Germany, 11.10.2017.
522. Circulating cell-free DNA in cancer and transplantation.
WASPaLM/IFCC joint symposium: “Genomic analysis in personalized diagnostics”.
23rd International Congress of Clinical Chemistry and Laboratory Medicine (IFCC
WorldLab 2017), Durban, South Africa, 23.10.17.
523. Circulating cell-free DNA as a diagnostic tool in transplantation.
Lecture. The Trinity College 2017 Master of Science Course in Clinical Chemistry.
Dublin, Ireland, 03.11.2017.
524. Circulating cell-free DNA as a diagnostic tool in cancer.
Lecture. The Trinity College 2017 Master of Science Course in Clinical Chemistry.
Dublin, Ireland, 03.11.2017.
525. Value proposition for advanced molecular diagnostics in cancer and transplantation.
Symposium “Adding value to laboratory medicine and pathology practice”. The 29th
World Congress of World Association of Societies of Pathology and Laboratory
Medicine (WASPaLM2017). Kyoto, Japan, 17.11.2017.

526. Graft-derived cell-free DNA as a diagnostic tool in transplantation.
Symposium "Liquid biopsy and micro RNA". The 29th World Congress of World Association of Societies of Pathology and Laboratory Medicine (WASPaLM2017).
Kyoto, Japan, 17.11.2017.
527. Biomarker in der Onkologie zur zielgerichteten Therapie.
Session Instand 1-2: „Moderne Labordiagnostik: Neueste Entwicklungen“.
Jahressymposium der INSTAND 2018. Frankfurt, Germany, 01.03.2018.
528. Möglichkeiten der Liquid Biopsy am Beispiel der Nierentransplantation.
Advisory Board Meeting „Liquid Biopsy in der Transplantationsmedizin“. Liquid Biopsy Center GmbH / amedes, Göttingen, Germany, 23.03.2018.
529. Circulating cell-free DNA as a diagnostic tool in cancer and transplantation.
VCU Pathology Grand Round. Virginia Commonwealth University, Richmond, USA, 14.05.2018.
530. Molekulare labormedizinische Diagnostik der Transplantatrejektion.
DELAB-Fachtagung „Neuheiten in der Labormedizinischen Analytik“. DELAB GmbH & Co. KG. Mainz, Germany, 16.06.2018.
531. Advances in the use of GcfDNA in transplantation.
Session II, 22nd ISE International Conference "All Aspects of Laboratory Medicine".
Naxos, Greece, 01.07.2018.
532. Graft-derived cell-free DNA – a promising noninvasive marker for detection of acute rejection and graft injury after solid organ transplantation.
Session "Emerging clinical applications of circulating DNA analysis". Track "Genomics/Genetics". 70th AACC Annual Scientific Meeting & Clinical Lab Expo. Chicago, USA, 30.07.2018.
533. Absolute quantification of graft-derived cell-free DNA as a marker of rejection and graft injury in kidney transplantation – results from a prospective observational trial.
Scientific Session "Invited oral abstracts: molecular diagnostics and genomics". 70th AACC Annual Scientific Meeting & Clinical Lab Expo. Chicago, USA, 31.07.2018.
534. Value proposition for advanced molecular diagnostics in cancer and transplantation.
Plenary Session "Technological transfer in clinical laboratory". XI National Conference of Clinical Laboratory with international participation. Plovdiv, Bulgaria, 28.09.18.
535. Möglichkeiten der Liquid Biopsy in der Organtransplantation.
Göttinger Tabler / amedes. Göttingen, 04.10.18.
536. Laboratory medicine – challenges and opportunities.
Opening lecture. 5th EFLM-UEMS European Joint Congress in Laboratory Medicine. Antalya, Turkey, 10.10.18.

537. Graft-derived cell-free DNA – a promising noninvasive marker for detection of acute rejection and graft injury after solid organ transplantation.
Symposium “AACC-KSLM select session: Emerging clinical applications for circulating DNA analysis”. LMCE 2018 & KSLM 59th Annual Meeting. Seoul, South Korea, 02.11.18.
538. Circulating cell-free DNA – a promising tool in cancer and transplantation.
Laboratory Session of the 10th Synevo Clinical Trials Symposium. Synevo Central Labs. Bucharest, Romania, 09.11.18.
539. Circulating cell-free DNA - diagnostic and prognostic applications in personalized cancer therapy.
Conference track “Companion Diagnostics for Immuno-Oncology”, session “Biomarkers for companion diagnostics”. 7th International Molecular Diagnostics Europe conference. Lisbon, Portugal, 08.05.19.
540. Graft-derived cell-free DNA as a biomarker in organ transplantation.
Conference track “Clinical Applications of Circulating Biomarkers”, session “Non-oncology applications: brain injury and transplantation”. 7th International Molecular Diagnostics Europe conference. Lisbon, Portugal, 09.05.19.
541. Value proposition for advanced molecular diagnostics in cancer.
Session II, 23rd ISE International Conference on Laboratory Medicine and Pathobiology. Chios, Greece, 30.06.2019.
542. Liquid Biopsy in der Organtransplantation.
Seminar. Chirurgische Universitätsklinik, Universitätsklinikum Knappschafts-krankenhaus Bochum der Ruhr-Universität Bochum, 30.07.2019.
543. Molecular oncology: challenges, rewards and value.
Scientific Session “The Value Proposition: actionable strategies for enhancing the value of laboratory medicine”. 71st AACC Annual Scientific Meeting & Clinical Lab Expo. Anaheim, USA, 06.08.2019.
544. The value proposition – EGFR testing in non-small cell lung cancer.
Symposium 8: “Demonstrating the value of laboratory medicine”. The 30th World Congress of World Association of Societies of Pathology and Laboratory Medicine (WASPaLM2019). Xi’An, China, 20.09.2019.
545. Donor-derived cell-free DNA as a biomarker in organ transplantation.
Closing plenary lecture. The Association for Mass Spectrometry: Applications to the Clinical Lab (MSACL) 6th European Congress & Exhibits (MSACL 2019 EU). Salzburg, Austria, 26.09.2019.
546. Circulating cell-free DNA – diagnostic and prognostic applications in personalized cancer therapy.
Opening lecture. XII Annual National Conference of the Bulgarian Society for Clinical Laboratory (BSCL). Burgas (Marina Cape Resort), Bulgaria, 04.10.2019.

547. Cell free DNA in der Nephrologie.
Sitzung “Infektiologische und immunologische Probleme bei der Nierentransplantation”. 11. Jahrestagung der Deutschen Gesellschaft für Nephrologie. Düsseldorf, 12.10.2019.
548. Graft-derived cell-free DNA as a marker for detection of rejection and graft injury after solid organ transplantation.
Session 6: “Liquid biopsy & transplantation”. 5th Congress of the European Society of Pharmacogenomics and Personalised Therapy (ESPT). Sevilla, Spain, 17.10.2019.
549. Circulating cell-free DNA as a diagnostic tool in cancer.
Lecture. The Trinity College 2019 Master of Science Course in Clinical Chemistry. Dublin, Ireland, 15.11.2019.
550. Circulating cell-free DNA as a diagnostic tool in transplantation.
Lecture. The Trinity College 2019 Master of Science Course in Clinical Chemistry. Dublin, Ireland, 15.11.2019.
551. Value proposition for advanced molecular diagnostics in non-small cell lung cancer.
Track 1: “Circulating tumor DNA + liquid biopsy”. Genomics Live 2019. Basel, Switzerland, 04.12.2019.
552. Donor-derived cell-free DNA for detection of graft injury.
42. Symposium “Interdisciplinary Study Group Renal Transplantation in Paediatrics”, CERTAIN (Cooperative European Paediatric Renal Transplant Initiative), Heidelberg, Germany, 06.12.2019.
553. Donor-derived cell-free DNA testing in organ transplantation: A value proposition.
Session “Personalization, Pharmacogenetics and Pharmacogenomics”. Biotech Atelier 2020. Sofia, Bulgaria (virtual meeting), 25.09.2020.
554. Spenderspezifische zellfreie DNA, Sitzung “Biomarker in der Transplantation“.
29. Jahrestagung der Deutschen Transplantationsgesellschaft. Cologne, Germany (virtual meeting), 16.10.2020.
555. Donor-derived cell-free DNA as a biomarker in organ transplantation.
Session “Liquid Biopsy”. Genomics Live. Basel, Switzerland (virtual meeting), 10.11.2020.
556. Donor-derived cell-free DNA testing in organ transplantation: A value proposition.
Scientific Session “New Strategies in Transplant Patient Monitoring”. 2020 AACC Annual Scientific Meeting & Clinical Lab Expo. Chicago, USA (virtual meeting), 14.12.2020.
557. Zellfreie Transplantat-DNA als Biomarker in der Organtransplantation.
11. Transplantationssymposium der Astellas Pharma GmbH, Sitzung 1, Aktuelles aus Forschung und Wissenschaft, Frankfurt (virtual meeting), 23.02.21

558. Spenderspezifische zellfreie DNA in der Nierentransplantation.
Komplex II, Antikörper-vermittelte Rejektion, 13. Charité-Nierentransplantations-Symposium, Berlin (virtual meeting), 18.06.21
559. Donor-derived cell-free DNA testing in organ transplantation.
KOL (key opinion leader) webinar, LifeSci advisors, New York (virtual meeting), 22.09.21
560. Donor-derived cell-free DNA testing in organ transplantation.
Molecular Diagnosis Centre, Department of Laboratory Medicine, National University Hospital, NUHS (National University Health System), Singapore (virtual meeting), 23.09.21
561. Circulating cell-free DNA as a diagnostic tool in transplantation.
Lecture. The Trinity College 2021 Master of Science Course in Clinical Chemistry. Dublin, Ireland (virtual meeting), 26.11.2021.
562. Circulating cell-free DNA as a diagnostic tool in cancer.
Lecture. The Trinity College 2021 Master of Science Course in Clinical Chemistry. Dublin, Ireland (virtual meeting), 26.11.2021.
563. Donor-derived cell-free DNA as a biomarker in transplantation to improve personalized immunosuppression.
Session I - 24th ISE Annual International Conference on Laboratory Medicine and Pathobiology: An Expert forum on Innovation in Clinical and Laboratory Medical Sciences.
Athens, Greece (virtual meeting), 10.12.2021.
564. Donor-derived cell-free DNA as a biomarker in transplantation to improve personalized immunosuppression.
EFLM Syllabus Course (Module: Organ Transplantation)
EFLM: European Federation of Clinical Chemistry and Laboratory Medicine, online presentation in January 2022
565. Donor-derived cell-free DNA testing in organ transplantation: a value proposition.
The 10th Santorini Conference, Session 1 Liquid Biopsy, Past, Present, Future Santorini, Greece, 24.05.22
566. Donor-derived cell-free DNA in transplant diagnostics.
Liquid biopsy forum, Curtis & Wyss
Valencia, Spain (virtual meeting), 09.06.2022
567. Donor-derived cell-free DNA testing in organ transplantation.
25th ISE International Conference on Laboratory Medicine and Pathobiology. Session 2
Samos Island, Greece, 09.07.22
568. Donor-derived cell-free DNA testing in organ transplantation.
BioTechX Congress 2022, Session "Liquid Biopsy". Genomics Live.
Basel, Switzerland, 08.11.22

569. Are we winning the war against cancer, Chair, Panel discussion.
BioTechX Congress 2022, Session “Liquid Biopsy”. Genomics Live.
Basel, Switzerland, 08.11.22
570. Liquid Biopsy: Wege zur breiteren Anwendung / Pathways to wider application.
Podiumsdiskussion
Biotech Innovation Spotlight, Liquid Biopsy
Berlin, Germany (virtual meeting), 22.11.22
571. Donor-derived cell-free DNA testing in organ transplantation.
The 5th International Meeting on Cell-Free DNA, cfDNA2023
Copenhagen, Denmark, 25.05.23
572. Liquid biopsy in cancer and transplantation.
26th ISE International Conference on Laboratory Medicine and Pathobiology.
Session 3
Sitia, Crete Island, Greece, 09.07.23
573. Circulating cell-free DNA – diagnostic applications in personalized cancer therapy and transplantation.
Princess Margaret Cancer Centre Seminar Series, UHN
Toronto, Canada, 14.09.23
574. Donor-derived cell-free DNA in Transplantation - current status and trends -.
BioTechX Congress 2023, Session “Liquid Biopsy” (chaired by M. Oellerich).
Basel, Switzerland, 05.10.23
575. Stellenwert der Donor-derived Cell-free DNA in der Nierentransplantation.
23. Transplantations-Workshop.
Freiburg (Munzingen), Germany, 25.11.23
576. Cell Free DNA – Performance characteristics and clinical applications, DNS annual update 2024 at All India Institute of Medical Sciences (AIIMS).
New Delhi, India, 07.04.24
577. Donor-derived cell-free DNA.
Oncocyte
Nashville, USA, 20.06.24
578. Update on cell-free DNA in cancer and kidney transplantation.
27th ISE International Conference on Laboratory Medicine and Pathobiology: An Expert forum on Innovation in Clinical and Laboratory Medical Sciences.
Milos Island, Greece, 08.07.24
579. Donor-derived cell-free DNA in transplantation to personalize immunosuppression.
Virtual meeting with the UK solid organ transplant expert group (ISOU),
London, UK, 30.09.24

580. Donor-derived cell-free DNA in transplantation to improve personalized immunosuppression.
BioTechX Congress 2024, Session “Precision Medicine Diagnostics and Therapies”.
Basel, Switzerland, 10.10.24
581. Donor-derived cell-free DNA to personalized immunosuppression in transplantation.
Track 6: Liquid biopsies for early detection, diagnosis and disease monitoring.
Nextgen Omics 2024 by Oxford Global.
London, United Kingdom, 25.10.24
582. Panel Discussion: Using Liquid Biopsy for Cancer. Moderator: Michael Oellerich
Track 6: Liquid biopsies for early detection, diagnosis and disease monitoring.
Nextgen Omics 2024 by Oxford Global.
London, United Kingdom, 25.10.24
583. Donor-derived cell-free DNA in transplantation for personalized immunosuppression in transplantation.
ESOT Webinar: Challenges and scientific advancements in biomarkers pediatric transplantation.
Live Stream, 26.11.24
584. Donor-derived cell-free DNA in transplantation for personalized immunosuppression in transplantation.
Precision Transplantation Path to Tolerance-Symposium.
University of British Columbia, Genome Canada
Vancouver, Canada, 02.12.24
585. Transplantation medicine and cfDNA is it useful?
Delhi Nephrology Society Annual Conference 2025
Faridabad, India, 12.04.25
586. Donor-derived cell-free DNA in transplantation for personalized immunosuppression in transplantation.
Plenary Session 2025 Congress of Chinese Medical Doctor Association of Laboratory Medicine.
Suzhou, China, 07.06.25
587. Transplantation medicine and cfDNA is it useful?
7th Dutch Cell Free DNA Day
Utrecht, Netherlands, 04.07.25
588. Donor-derived cell-free DNA in transplantation for personalized immunosuppression in transplantation.
Seminar. Department of Clinical Chemistry, Inselspital, Bern University Hospital.
Bern, Switzerland, 28.08.25
589. Donor-derived cell-free DNA in transplantation for personalized immunosuppression in transplantation.
Seminar at National University Hospital,
Singapore, Singapore, 23.09.25

590. Donor-derived cell-free DNA in transplantation for personalized immunosuppression in transplantation.
23rd International Congress of Therapeutic Drug Monitoring and Clinical Toxicology, iMDx Industry Workshop.
Singapore, Singapore, 24.09.25